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In animals, disease progression can be influenced by genetics, environment,
management practices, and the type of pathogen. Infection with porcine circovirus 2
(PCV2) causes development of diseases known as porcine circovirus 2-associated
diseases (PCVAD), for which there is currently no treatment. In Trial 1, weanling
unvaccinated barrows and gilts (n = 229) from two genetic lines were bled at d14, 49, and
at necropsy to assess disease progression from natural infection using antibodies (ELISA)
and viral copy counts (quantitative PCR). Virus was isolated from infected pigs and
sequenced to determine the strain responsible for infection. At d49, 113 animals had
active infection. At necropsy, clinical signs of infection were found in 16% of the pigs. In
Trial 2, barrows from two genetic lines (n = 81) were infected with an inoculate known to
cause PCVAD. Blood and weights were collected before infection and at d7, 14, 21, and
28 to characterize response. Pigs were classified as early responders (n = 33), late
responders (n = 40), and non-responders (n = 7) based on IgM levels. Other traits were
fitted to a mixed model with effects of group and line, and random effect of litter. Means
of viral load throughout the 28-day period differed (P < 0.01) between early and late

responders and non-responders. Viremia differed among groups (P < 0.01) at d14, 21,
and 28. Viremia of non-responders was 18% less than early and late responders at d14,
and 22% less at d21. Non-responders tended to have greater growth rate than the other
groups. Variation in immune response can be utilized in genomics studies to identify
genetic markers for disease resistance that can be used to select for disease resistance.
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1
INTRODUCTION
Porcine circoviruses (PCV) are members of the genus Circovirus and the family
Circoviridae. The most notable of the porcine circoviruses is porcine circovirus type 2,
PCV2, which has been associated with several disease syndromes since its initial
classification in 1996. The genome contains single-stranded, non-enveloped, circular
DNA molecules, and is 1768 nucleotides in size (Gillespie et al., 2009). Two major openreading frames have been identified; open-reading frame 1 encodes for proteins involved
in viral replication, and open-reading frame 2 encodes the capsid protein surrounding the
virus (Carman et al., 2008).
Porcine circovirus 2 is further classified into two categories, a and b, with a first
detected in North America, and b first detected in Europe (Takahagi et al., 2009). It has
been demonstrated in field studies and previous research that PCV2a is the less virulent
strain of the virus. The other category, PCV2b, is most usually defined as the etiological
agent of PCVAD, porcine circovirus associated diseases.
The most common characteristics in all PCV2 infections are signs of lymphoid
depletion and lymphopenia in circulating blood. The virus is able to attack the immune
system by affecting both macrophages and dendritic cells. Although PCV2 is observable
in these cells, it has been suggested that they are not the sites of viral replication. Several
studies have indicated that dendritic cells may be the source of transportation for viral
cells. However, not much is known about the pathogenesis of the PCV2 virus (Opriessnig
et al., 2007).
Porcine circovirus associated diseases affect several biological systems in the pig.
First, the porcine respiratory disease complex (PRDC) has been linked to infection with
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PCV2. Also, PCV2 can cause gastrointestinal complications in the form of PCV2associated enteritis, reproductive issues in the form of PCV2-associated reproductive
failure, and a vascular disease known as porcine dermatitis and nephropathy syndrome.
The most notable disease syndrome caused by PCV2 infection is known as post-weaning
multisystemic wasting syndrome (PMWS). This disease state causes a wasting condition
in which pigs are unable to put on adequate weight and exhibit depletion in lymphocytes
leading to an inability to fight off other infections.
The development of PCVAD is reliant on many factors. Many strains of PCV2b
have been isolated and sequenced, and a difference in virulence among the strains can
affect the severity of the virus and thus the severity of disease conditions. There is also a
genetic effect, in which certain breeds are more susceptible to the disease than others.
Studies have indicated a vast difference in the development of clinical signs in pigs of
varying breeds including Large White, Pietrain, Duroc, and Landrace. Co-infections with
other viruses or bacteria such as Mycoplasma hyopneumoniae, porcine parvovirus,
porcine reproductive and respiratory disease, and swine influenza can all affect disease
progression of PCV2. Host factors, such as the amount of maternal antibodies acquired
from colostrum in the first hours of life, can have an effect on the development of PCV2
associated diseases.
A vaccination protocol for PCV2 exists. Four commercially available vaccines are
on the market, with the first being approved for use in the United States in 2007. The
vaccines vary in dosing, antigen content, and the age of pig for which they are licensed.
Vaccinations have been proven successful in lowering mortality rates in both field studies
and farm applications (Takahagi et al., 2009). However, every pig in the herd must be
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vaccinated in order to prevent an outbreak, even though many pigs contract the virus and
show no clinical signs. The use of selection to eliminate the need for vaccines against
PCV2 would be ideal to save the swine industry millions in vaccination costs yearly.
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1.1 LITERATURE REVIEW
Characteristics of PCV2
Porcine Circovirus (PCV) emerged in 1974, initially as a contaminant of the
porcine kidney cell line PK-15 (Grau-Roma et al., 2010). This PK-15 PCV isolate did not
elicit clinical disease in pigs in experimental challenges. Allan et al., 1995, demonstrated
that infecting pigs with PCV that were Cesarean-delivered and colostrum-deprived
resulted in replication of the virus, but no lesions or disease state was induced (Sorden,
2000).
In 1991, post-weaning multisystemic wasting syndrome, PMWS, emerged and
was known to be associated with a circovirus (Allan and Ellis, 2000). Sequence analysis
comparison of the two virus strains showed that the sequence from PCV and the one
causing PMWS had 75-76% nucleotide sequence identity. This lead to the discovery of
another type of circovirus; the non-pathogenic virus became PCV1 and the new virus
became PCV2 (Opriessnig et al., 2006a). In addition to the two types, PCV2 can be
broken down into two categories: PCV2a, detected in North America, and PCV2b,
detected in Europe (Takahagi et al., 2009). According to Grau-Roma et al. (2010), studies
show that PCV2b is more prevalent in natural infections of herds. Therefore, PCV2b may
have higher virulence than PCV2a.
The porcine circoviruses are members of the genus Circovirus of the family
Circoviridae. Other members of the genus Circovirus include beak and feather disease
virus, canary circovirus, goose circovirus, and pigeon circovirus (Opriessnig et al., 2007).
The Circoviridae family genomes contain single stranded, non-enveloped DNA
molecules that are circular in shape and range in size from 1.8 to 2.3 kilobases
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(Opriessnig et al., 2007). Because the DNA molecules are non-enveloped, the virus is
resistant to many disinfectants, such as those with alcohol, chlorhexidine, iodine, and
phenol bases (Grau-Roma et al., 2010). The virion DNA is single-stranded and negative
sense, with 1,800 bases and six open reading frames (Chae, 2005). Porcine circovirus was
discovered to be the smallest virus capable of replicating independently in mammalian
cells (Kim et al., 2004b).
Porcine circoviruses can be divided into type 1 or 2. Type 1 is generally regarded
as non-pathogenic, while type 2 is considered pathogenic. Type 1 and 2 share about 75
percent nucleotide sequence identity (Opriessnig et al., 2006b). Because Type 1 has not
been shown to induce a disease in swine, research has been more focused on Type 2 as
the cause of several diseases (Finsterbusch and Mankertz, 2009).
PCV2 is an icosahedral, non-enveloped virion (Takahagi et al., 2009). Isolates of
PCV2 have genomes ranging from 1767 to 1768 base pairs (Opriessnig et al., 2006b).
The virion is about 17 nm in diameter (Takahagi et al., 2009). There are two major open
reading frames that are associated with PCV2. The first, open reading frame 1 (ORF1),
enables viral replication by encoding for replication proteins. Open reading frame 2
(ORF2) encodes the capsid protein to surround the virus (Carman et al., 2008).
Infection with PCV2 is complex in that infected pigs can remain asymptomatic.
Pigs that are highly viremic with PCV2 DNA may develop diseases associated with
PCV2 infection. These diseases have been classified as Porcine Circovirus 2 Associated
Diseases (PCVAD), and include PMWS, PDNS, PCV2-associated reproductive failure,
PCV2-associated enteritis, and porcine respiratory disease complex (PRDC).
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Pathogenesis
The development and step-by-step events leading to infection and replication of
PCV2 are somewhat unclear to scientists. It seems that the disease consistently causes
lymphoid depletion and low levels of lymphocytes in peripheral blood. Reduction of
lymphocytes in infected pigs can be attributed to several factors, including reduced
production in the bone marrow, reduced proliferation in secondary lymphoid tissues, or
increased loss of lymphocytes in areas such as the bone marrow, peripheral blood, or
secondary lymphoid tissues (Opriessnig et al., 2007).
Dendritic cells have a distinctive ability to start an immune response and control
homeostasis within lymphoctyes. Because they are highly networked in many locations
such as the skin, mucosal surfaces, and circulating in blood, dendritic cells are able to
deal with viruses rapidly once they have been encountered. This cell type is responsible
for encapsulating antigens and travelling to lymph nodes and organs to activate T cells
for an increased immune response (Vincent et al., 2003). In the study carried out by
Vincent and others in 2003, it was determined that both bone-marrow-derived and
monocyte-derived dendritic cells are affected by PCV2 infection. In the Opriessnig et al.
(2007) review, it was further described from Vincent’s study that replication in dendritic
cells could not be proven. However, PCV2 was able to persist in the cells without
undergoing induction of apoptosis. It was suggested that dendritic cells might be utilized
as vehicles for transportation because of their migratory ability.
Porcine circovirus 2 manifests itself in both macrophages and dendritic cells, but
studies using in vitro models have found that monocytes may not be the site of PCV2
replication (Opriessnig et al., 2007). The review by Opriessnig et al., 2007, describes in
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detail the work of Gilpin and others, 2003, in which macrophages and monocytes were
tested for their facilitation of PCV2 replication. In that study, replication was not
observed, but neither was degradation in the cytoplasm of both monocytes and
macrophages.
Fenaux and others in 2002 developed an infectious clone of PCV2 to help
understand the role of PCV2 in systemic diseases. They infected specific pathogen-free
pigs with cloned genomic PCV2 DNA by direct injection into the livers and superficial
iliac lymph nodes. After 35 days post infection (d.p.i.), PCV2 antigen was detected in a
variety of tissues and organs in the pigs, and lesions were found on both the lungs and
lymph nodes. This study was groundbreaking because it illustrated that in vivo
transfection could be used to study the relationships of PCV2 genes to assess their roles
in both virus replication and pathogenesis.
Not clearly understood is the reason that some pigs will develop clinical signs of
the disease upon infection, whereas other pigs will not manifest any signs. Porcine
circovirus 2b has been shown to be influenced by several factors that can either enhance
or prevent spread of the virus. These aspects, as explained by Opriessnig and others in the
2007 review, are: virus-dependent factors, host-dependent factors, effect of coinfections,
and effect of immune modulation.

Influential Factors - Virulence
Virus dependent factors can have an effect on the pathogenicity and transmission
of PCV2. Virulence fluctuates from strain to strain; one isolate can infect a whole herd of
pigs, whereas another isolate can have no clinical manifestations. It has been reported
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that most herds in the United States are infected with PCV2 (Allan and Ellis, 2000;
Opriessnig et al., 2006a), but many herds do not exhibit PCV2-associated diseases,
whereas other farms report high occurrence and high mortality numbers (Larochelle et
al., 2003; Opriessnig et al., 2006a).
A study by Opriessnig and others (2006b) compared two isolates, PCV2-40895
and PCV2-4838, both of which were defined as PCV2a. The isolate PCV2-40895 was
taken from a pig diagnosed with post-weaning multisystemic wasting syndrome, a PCVassociated disease. The pig had lymphoid depletion, histiocytic replacement of lymphoid
follicles, and high PCV2 antigen counts. The second isolate, 4838, was taken from a pig
from an Iowa farm that suffered from respiratory disease. Streptococcus suis, Pasteruella
multiocide, and Mycoplasma hyopneumoniae were isolated from this pig. The pig did not
show signs of PCV2-associated lymphoid lesions, but did test positive for PCV2 DNA.
Viruses from both animals were sequenced and the genomes for both were found
to be 1768 base pairs. In open reading frame (ORF) 1, the two isolates had 98.9 percent
sequence identity and had only 19 sequence differences. The sequence differences
resulted in five nucleotide differences; two caused amino acid shifts. The ORF 2 capsid
gene of the two isolates shared 98 percent nucleotide identity and 96.1 percent amino
acid identity. This study demonstrated that two strains that are genetically somewhat
similar could have a variety of effects on the host.
Following this study, Opriessnig and others in 2008 conducted a study in which
the same strains, now referred to as ISU-40895 and ISU-4838, were used, as well as NC16845 and Can-17639. The strain NC-16845 was isolated from a group of pigs showing a
history of severe respiratory disease, specifically lymphadenitis and bronchointerstitial

9
pneumonia. The strain Can-17639 was taken from a group of pigs demonstrating wasting,
coughing, and bronchointerstitial pneumonia. While ISU-40895 and ISU-4838 were
classified as PCV2a, NC-16845 and Can-17639 were classified as PCV2b. One hundred
and thirteen pigs were used for the study and were inoculated with one of the four virus
isolates. Upon necropsy and sequencing, it was determined that the four genome
sequences shared 95.7% identity. The two PCV2b isolates alone shared 99.9% nucleotide
sequence identity. However, because none of the isolates generated clinical symptoms,
and because there were no differences in macroscopic lesions between groups, the results
of the study only shed light on the differences between the strains, not their effects.
Another study published by Grierson and others (2004) looked at 10 isolates of
PCV2 in the Netherlands from four farms with clinical signs of PMWS and six farms
without. The virus was isolated and sequenced in each case, and the sequences were
aligned. It was found that the 10 strains of PCV2 had 95.6 to 100% sequence identity.
However, because the strains were causing symptoms on some of the farms and no
symptoms on the others, and they were genetically very similar or exactly similar, it was
concluded that small differences in nucleotide sequences of PCV2 do not fully elucidate
why some pigs show symptoms and others do not.
Last, de Boisseson and others in 2004 looked at 23 herds in the region of Brittany
in France. The virus from each herd was isolated and sequenced. It was noted that 10 of
the isolates did not cause signs of PMWS and were recorded as PMWS – (negative).
Thirteen of the strains did cause PMWS and were known as PMWS + (positive) cases. It
was found that there was a broader nucleotide diversity (94.6 to 99.9% sequence identity)
in the PMWS – pigs as compared to a nucleotide diversity of 99.5 to 99.9% in the
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PMWS + pigs. Also, two clusters were identified that the sequences of strains fit clearly
into. Interestingly, Cluster I contained the strains from France, the United Kingdom, and
The Netherlands exclusively, while in Cluster II fit the strains from North America, Asia,
Germany, and Spain. This study concluded that different strains of PCV2 have variable
effects on the development of PMWS—some infected pigs showed signs of the disease
and others did not.

Influential Factors - Breed Differences
Host susceptibility has been shown to affect disease progression of PCV2.
Previous research has demonstrated that every pig breed around the world is susceptible
to infection with PCV2. However, the degree of susceptibility appears to vary across
breeds.
In a study by Opriessnig and others (2006a), three breeds were tested to determine
whether there is a difference in susceptibility to PCV2 infection and development of
PCV2 associated diseases. The three groups of purebreds used were Duroc, Landrace,
and Large White because they represent the genetic make-up of a large percentage of
commercial swine herds in the United States. Pigs were inoculated with a single strain of
PCV2 (ISU-40895) and then scored for clinical symptoms, tested serologically, and
underwent histological examination and immunohistochemical analysis. It was found that
Landrace pigs had significantly more severe lymphoid depletion in the tonsillar region as
well as in the lymph node pool. Also, microscopic lesions that were characteristic of
PMWS developed in 15.8% of the Landrace pigs, whereas none of the Duroc and Large
White pigs developed these lesions. These three Landrace pigs also experienced moderate
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to severe granulomatous enteritis, as well as moderate lymphohistiocytic inflammation in
the kidney and thymus. There were no significant differences in the susceptibility to
PCV2, as measured by viremia, genomic DNA copy counts, and anti-PCV2 antibody
levels. Nevertheless, there was a difference in the amount of lesions consistent with
PMWS that developed in the Landrace pigs versus the Duroc and Large White pigs. So
while Landrace pigs are no more susceptible to contracting the virus, they may have a
higher vulnerability for PCVAD.
Opriessnig and others (2009a) continued breed susceptibility research by
conducting a study using 39 Landrace and 39 Pietrain pigs. The pigs were inoculated
with the same strain as the one used in the previous study (ISU-40895), were clinically
evaluated, slaughtered, and underwent histopathology, lymphoid lesion scoring, and
immunohistochemistry. For the Pietrain pigs, 34.6% had mild depletion of lymph node
follicles. However, 30.7% of Landrace pigs had moderate to severe lymphoid depletion.
In addition, Landrace pigs experienced a variety of lesions that were scored as mild
(n = 6), moderate (n = 5), and severe (n = 1), whereas the Pietrain pigs had only mild
lesions (n = 9). The study results imply that the Landrace breed demonstrates a higher
susceptibility to the development of lesions associated with PCV2 infection. It also
indicates that Pietrain pigs have the propensity for becoming infected with the virus and
not developing histopathological symptoms.
A study by Rose and others in 2005 used 540 pigs that were born to Pietrain or
random boars and random sows known as X and Y. The study consisted of clinical
evaluations and serology. It was found that the average rate of occurrence of PMWS
overall was 18%. In addition, the morbidity rate in the X-derived pigs was 17.3%, while
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the morbidity rate in Pietrain pigs was 16.3%. This study demonstrated that Pietrain pigs
might have some genetic capability to stop the development of PCVAD, although further
testing is needed to confirm this finding.

Influential Factors - Maternally Derived Antibodies
Sows have the ability to pass on immunity to their piglets through colostrum
secreted shortly after birth. Passively acquired antibodies can bolster the immune
system’s ability to ward off viruses (McKeown et al., 2005).
McKeown and others (2005) conducted a study to determine the role of
maternally-derived antibodies in the prevention of PCV2 infection. The study utilized
106 piglets that were separated based on antibody titers and infected with a PCV2
inoculate. Piglets in group A were considered negative for maternal antibodies, group B
had low antibodies, and groups C and D had high antibody levels. Groups A, B, and C
were infected at d0 and d42. Group D was not infected with the virus until d42. The
piglets in group A experienced seroconversion by 42 days post infection (d.p.i.),
indicating presence of infection. The low maternal antibodies in group B had waned by
14 d.p.i., and by 42 d.p.i., four of the five piglets had PCV2 DNA. For group C, the high
antibody pigs, only two of the eight piglets had PCV2 viremia by 42 d.p.i. In group D,
who were inoculated later than the other groups, all five pigs became infected with PCV2
after infection at d42, when the initial maternal antibodies had waned.
At the time of second challenge for groups A, B, and C, at d 42, all but group C
were negative for maternal antibodies, and only two group C pigs became viremic. The
results of this study indicated that piglets exposed to PCV2 with little or no maternal

13
antibodies did not have protection against the virus, and therefore exhibited
seroconversion and became viremic.
In a study described by Calsamiglia et al. (2007), 15 sows from seven farms were
chosen and after farrowing, the piglets were followed up to seven months of age.
Pathological exams were performed to check for signs of PMWS. Forty of the 63 piglets
that lived to the seven-month mark and sent to necropsy (63.5%) were diagnosed as
having PMWS. However, 36 out of 38 (94.7%) sows that had piglets live were tested and
found PCV2 negative. Thirty-two out of the 38 (84.2%) had antibody titers in the
medium to high range. In the group of sows that had piglets die before the seven-month
study was finished, only 2 of 7 (28.6%) had medium to high antibody titers. It was
observed that increasing maternal immunity and decreasing sow infection status could
lessen the propensity for PWMS.
Opriessnig and others (2004a) designed an experiment where the objective was to
deliver piglets negative for PCV2 from sows positive for PCV2. Among other
characteristics, sow herd antibody profiles, the transfer of passive antibodies, and
maternal antibody decay were measured. Viremic conditions were not found in the
piglets, and the authors suggested that passively-acquired antibodies may be able to stop
PCV2 replication until the levels of maternal antibodies decrease. At this time, piglets
would be able to develop clinical symptoms of PCV2 and could experience progression
to PCVAD.
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Influential Factors - Co-infection
Porcine circovirus 2 has been found to act as a co-infecting agent in conjunction
with other viruses and bacteria. According to a review published by Grau-Roma et al. in
2010, there are at least eight viruses, three mycoplasmas, and three bacterial agents that
have been found as co-infectors in PMWS cases. These viruses include PRRSV, PPV,
porcine epidemic diarrhea virus, Aujeszky’s disease virus, Hepatitis E virus, torque teno
virus (TTV), porcine teschovirus, and swine influenza virus (SIV). The Mycoplasma
most associated with PCV2 is Mycoplasma hyopneumoniae, although two others, M.
hyorhinis and M. suis have been noted as PCV2 co-infectors. Several bacteria, including
Salmonella cholera suis, Escherichia coli, and Haemophilus parasuis, have been found in
conjunction with PCV2.
In a field study completed by Pallares et al. in 2001 at the Iowa State Veterinary
Diagnostic Laboratory, the experimenters reviewed 4,688 tissue submissions for presence
of PCV2 and PMWS. Thirty-seven percent (1,751) of the tissues tested positive for PCV2
using immunohistochemistry. Conversely, 484 (10.3%) of the 4,688 samples tested
positive for PMWS. Most (80%) of the cases used in the study came from Iowa, followed
by North Carolina, Oklahoma, and Minnesota. Infection with both PCV2 and PRRSV
was the most common combination, with 164 cases; following that was PCV2 with M.
hyopneumoniae (92), PCV2 with bacterial septicemia (68), PCV2 with bacterial
pneumonia (37), and PCV2 with swine influenza. In addition, 77 pigs experienced
infections of PCV2, PRRSV, and M. hyopneumoniae. Only nine of 4,688 cases showed
singular infection of only PCV2. Of the 384 cases demonstrating PMWS, 369 ages were
provided. It was found that PMWS occurred between 8 and 18 weeks in 294 of the 369
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pigs. PMWS was found most in pigs 10 weeks of age. This age of presentation was
normally distributed and corresponds with the findings of other reports (Pallares, 2001).
A study by Krakowka and others (2000) looked at the effects of a dual infection
of PCV2 and PPV in gnotobiotic pigs. Twenty-six piglets delivered by C-section were
divided into infection groups, PCV1 alone (n = 3), PCV2 alone (n = 3), PPV alone
(n = 3), PCV1 and PPV (n = 4), PCV2 and PPV (n = 4), and PCV1 and PCV2 (n = 4).
Three pigs were kept as controls. Those pigs receiving only one infectious agent
remained normal, with only a small enlargement of the lymph nodes. The four piglets
receiving PCV1 and 2 together also remained clinically normal. Pigs inoculated with the
combination dose of PCV2 and PPV developed acute gross lesions characteristic of
PMWS. All four pigs developed a jaundice condition as well as subcutaneous edema.
This caused the need for euthanasia on 30 d.p.i.. Three of the four piglets in this group
experienced a decrease in thymic size, and three had moderate histological lesions. This
was vastly different from piglets receiving a single infectious dose. The piglets with PPV
alone never became viremic. Only half of the PCV1 pigs became viremic. This study
confirmed that PCV2 is the viral pathogen, because PCV1 was unable to manifest clinical
symptoms. Also, it was determined that in gnotobiotic piglets, the presence of PCV2 was
consistent in all PMWS cases, but not enough alone to cause clinical symptoms.
Numerous studies have been conducted to understand the importance of PRRSV
infection in the development of PCVAD. A brief report by Allan and others (2000)
explained attempts to infect colostrum-deprived piglets with both PCV2 and PRRSV.
Four pigs were inoculated with PRRSV alone, three with PCV2 alone, and five with an
equal mixture of PCV2 and PRRSV. In the pigs infected with one virus, no clinical
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disease or gross lesions developed. One pig with dual infection suffered from enlarged
lymph nodes, and thymic atrophy was observed in another dual infection pig. Also, as is
common with PMWS, lymphoid, liver, renal, and vascular lesion were seen in four of the
five PRRSV/PCV2 pigs. Because disease developed in only those pigs dually-infected, it
was suggested that infection with PRRSV could enhance the replication of PCV2 and
thus lead to clinical symptoms of PCVAD.
Another study consisting of PRRSV and PCV2 was conducted by Harms and
others in 2001. They utilized 59 piglets from 10 sows and placed them into four treatment
groups: controls (n = 10), PCV2 (n = 19), PRRSV (n = 13), and PCV2/PRRSV (n = 17).
No respiratory symptoms were noticed in the control pigs. The PCV2 pigs had mild
clinical respiratory disease. One pig from the PCV2 group died of severe exudative
epidermitis and three died from hemorrhagic gastric ulcers before the study was
completed. In addition, two pigs from the PCV2 group were euthanized early due to
severe depression, lethargy, and jaundice.
The PRRSV pigs developed acute respiratory problems after the seventh day post
infection that were significantly worse than the PCV2 and control pigs; however, no pigs
died or were euthanized from this group. The PCV2/PRRSV pigs had similar respiratory
problems to the PRRSV pigs. Between 10 and 20 d.p.i., 10 of 11 pigs contracted acute
dyspnea and depression. Four of these pigs died early, and six were euthanized for the
sake of animal welfare. The remaining PCV2/PRRSV pig died at 20 d.p.i.. The
PCV2/PRRSV pigs had more severe and recurrent hepatic lesions than PCV2 pigs, as
well as more severe lymphoid depletion. In addition, the dually infected pigs all
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experienced necrotizing hepatitis and interstitial pneumonia. It was concluded that
PRRSV could enhance the progression of PCV2 in the pig model.
A study by Opriessnig and others (2004b) incorporated 67 crossbred piglets into
four groups. Seventeen pigs received no inoculations, whereas 17 received Mycoplasma
hyopneumoniae alone, 16 received PCV2 alone, and 17 received an infectious dose
containing both M. hyopneumoniae and PCV2. Single M. hyopneumoniae infections
exhibited mild to moderate respiratory disease whereas in dual M. hyopneumoniae/PCV2
infections it was mild to severe. The severity of M. hyopneumoniae-associated lesions
were similar between single and dual infections. Pigs in the PCV2 alone group and the
dual infection group experienced a two to three times normal size enlargement of lymph
nodes. Pigs in the M. hyopneumoniae group did not illustrate this condition. All treatment
pigs developed interstitial pneumonia, and four of the 17 dually infected pigs showed
signs and lesions pertaining to PMWS. None of the PCV2 alone group exhibited signs of
PMWS. The authors concluded that M. hyopneumoniae could strengthen the effects of
PCV2 and lead to more severe clinical disease.
Last, Pogranichniy et al. (2002) conducted a field-based case control study in
which pigs from four to 16 weeks of age showing signs of PMWS were observed. Thirtyone infected pigs and 56 controls were utilized and tested for PCV2, PRRSV, PPV,
porcine enterovirus, SIV, porcine respiratory coronavirus (PRCV), transmissible
gastroenteritis virus (TGEV), porcine endogenous retrovirus (PERV), porcine
lymphotropic herpesvirus (PLHV), and bovine viral diarrhea virus (BVDV). All animals
tested positive for PERV, which is known as omnipresent in swine. Porcine circovirus 2
was present in 29 of 31 (94%) PMWS pigs, as well as in 35 of 56 (63%) controls. In
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addition, PRRSV was detected in 42% of the PMWS animals and 20% of the controls.
After statistical analysis, it was determined that the odds ratio for the association between
PCV2 and PMWS was 9.3, meaning that a pig with PCV2 is 9.3 times more likely to
develop PMWS as compared to pigs not viremic for PCV2. The analysis also indicated
that an animal is 31.2 times more likely to develop PMWS if infected by both PCV2 and
PRRSV.
All of these studies currently lead to no concrete conclusions about whether a
single pathogen perpetuates the infectious nature of PCV2. According to a review by
Opriessnig and others from 2007, it appears that several infectious agents of varying
pathogenicity play a role in the development and progression of PCVAD.

Transmission
Porcine circovirus 2 can be transmitted both horizontally and vertically. The high
occurrence of PCV2 viral DNA in herds across the world reaffirm the fact that PCV2 is
effective in terms of transmission (Kristensen et al., 2009). Horizontal transmission
occurs when infected and non-infected pigs are mixed together (Grau-Roma et al., 2010).
One study indicated that pigs kept in the same pen with direct contact were able to
transmit the disease to other pigs more efficiently than pigs in separate pens (Andraud et
al., 2008). The most common route of infection appears to be intra-nasally, although
PCV2 can be shed in tonsillar, bronchial, and ocular secretions. Feces, saliva, milk, and
semen have also been shown to contain PCV2 DNA and therefore could be modes of
transmission for PCV2 (Krakowka et al., 2000).
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In a study performed by Yang and others (2003), fecal and intestinal samples
were obtained from 97 piglets, 63 with signs of enteric disease and 34 piglets that had no
signs of gastrointestinal problems. Of the 63 piglets with enteric disease, 18 tested
positive via PCR for porcine circovirus. Because PCV2 DNA was present in 14 intestinal
samples and four fecal samples, it becomes evident that PCV2 can be shed in feces and
therefore can be transmitted in fecal matter.
The possible existence of a respiratory route of infection was demonstrated by
Magar and others in 2000, when they found that the virus is able to infect the
nasopharynx and tonsils. From there the virus was able to spread throughout the body by
way of blood or lymph (as reported in a review by Dupont et al., 2009).
Indirect infection, when pigs are kept in separate pens but can still spread the
disease, occurs as well. Kristensen and others (2009) conducted a study with 12 herds of
pigs where eight herds had signs of PMWS and four did not. In some cases, the pigs were
mixed inside the pens; in other cases, the non-PMWS pigs were placed in pens next to
PMWS-pigs; additionally, some affected pigs were kept in pens across the aisle from pigs
not affected by PMWS. When the pigs were mixed within the pens, 10 of 18 with direct
contact began to illicit signs of PMWS, while three of 18 in neighboring pens and one of
18 across the aisle also showed signs. This study concluded that direct and indirect
contact may induce clinical signs of PMWS.
Vertical transmission, from dam or sire to piglet, has been proven by several
studies. Trans-placental infection can occur after intra-nasal infection of pregnant sows
before farrowing (Ha et al., 2008). PCV2 was found in both pigs born alive and pigs that
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were aborted. Numerous studies have been conducted to find whether semen or
colostrum containing PCV2 DNA can be infectious to piglets.
Madson and others in 2009 implemented a study to attempt to induce infection in
PCV2-free sows by artificial insemination with PCV2-laced semen. Nine specific
pathogen-free sows underwent estrus synchronization and insemination using a dose of
semen mixed with three mL of either PCV2a or PCV2b. In the three sows inseminated
with semen and PCV2a, no piglets were born live, stillborn, or mummified. The sows
failed to maintain any pregnancy to gestation. In the three sows inseminated with semen
and PCV2b, 35 piglets were delivered; however, only eight were born alive, two were
stillborn, and 25 were mummified. Of the pigs coming from these dams, only the two
stillborns acquired lesions, and these were classified as due to chronic myocardial
dysfunction and cardiac dilatation. The authors concluded that intrauterine infection of
sows could induce viremia in both the sow and fetuses (Madson et al., 2009).
Larochelle et al. in 2000 and Schmoll et al. in 2008 indicated that PCV2 can be
shed in semen. In addition, a study performed by Patterson and others in 2010 sought to
demonstrate and understand shedding and infection dynamics of PCV2. They used 26
pigs and inoculated them with the virus in a variety of methods: pooled oral samples
using intraperitoneal (IP) administration, pooled fecal samples using IP, pooled nasal
samples using IP, pooled oral samples administered orally, pooled fecal samples
administered orally, pooled nasal samples administered intranasally (IN), and
intramuscular (IM) injections to administer the virus. All three sources of IP
administration resulted in PCV2 viremic conditions and seroconversion to anti-PCV2
antibodies. Nasal samples administered IN also resulted in PCV2 infection. Fecal
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samples administered orally resulted in infection in two of four pigs. One of the three
pigs with the IM injection became viremic. However, the oral samples administered
orally did not result in viremia for PCV2. The conclusions from the study were that
PCV2 is shed in large amounts nasally, orally, and in fecal secretions in an experimental
infection.
In a study performed by Opriessnig and others, the authors wanted to determine if
PCV2 was transmissible when fed to other pigs via meat and bone meal. Because PCV2
has been found in lymphoid tissue and bone marrow (Bolin et at., 2001), as well as in
heart tissue (Kennedy et al., 2000), it is important to know the relationship between oral
consumption and PCV2 infection. As found by Allan and others in 1994, PCV1 is stable
at a pH of 3, and because meats in slaughter houses and packing plants do not typically
reach a pH that low, it is likely that meat from a PCV2-positive animal could still contain
an infectious form of the virus through storage and possible use afterward (Opriessnig et
al., 2009b).
The authors collected tissue samples including skeletal muscle, spleen, tonsil,
lymph nodes, and bone marrow from three pigs previously infected with PCV2. Then,
they brought in 15 two-week old, colostrum-deprived crossbred piglets and separated
them into treatments based on the tissues they would consume: skeletal muscle orally,
bone marrow orally, lymphoid tissues orally, or PCV2 inoculate via a stomach tube.
Necropsy on the piglets was performed, and the virus from the pigs was isolated and
sequenced. It was found that consumption of PCV2 positive lymph nodes, bone marrow,
and skeletal muscle caused viremic conditions after only seven days. All of the pigs in the
study became PCV2 positive, and microscopic lesions due to lymphocytic depletion and
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histiocytic replacement of lymph follicles were found in nine of the 15 pigs. It was
determined that infection can be transmitted through uncooked skeletal muscle, bone
marrow, and lymphoid tissue by way of oral consumption by PCV2- naïve pigs.

Diseases Caused by PCV2
Post-weaning Multisystemic Wasting Syndrome
Post-weaning multisystemic wasting syndrome, known as PMWS, occurs
throughout the world (Chae, 2005). This disease was first discovered in 1991 in Canada,
and affects primarily piglets from five to twelve weeks old (Gagnon et al., 2007).
Symptoms of the disease include wasting and the inability to gain weight, enlargement of
the inguinal lymph nodes, jaundice, and lymphocytic depletion (Gagnon et al., 2008). In
addition, pigs with PMWS experience a decline in immunological function due to a
marked reduction in circulating lymphocytes (Takahagi et al., 2009). The disease
manifests itself in 10 to 30% of infected pigs (Darwich et al., 2004). This indicates that
many pigs have developed a susceptibility to the syndrome, despite infection with PCV2.
In herds that undergo an acute outbreak, mortality due to PMWS can reach 10%; in herds
that are endemically affected, mortality totals are lower (Allan and Ellis, 2000).
Post-weaning multisystemic wasting syndrome is characterized by lesions that
involve clusters of globular intracytoplasmic inclusion bodies (Sorden, 2000). Lymphoid
lesions can be found in almost all tissues of an infected animal, including the tonsils,
Peyer’s patches, spleen, thymus, and most commonly, lymph nodes (Darwich et al.,
2004). Existence of these lesions is indicative of PMWS; however, these lesions are not
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always present in an animal suffering from the disease. Therefore, there are several other
methods to precisely detect PCV2 infection that can lead to PMWS.
Post-weaning multisystemic wasting syndrome can manifest itself in a variety of
symptoms. When an infected animal is sent for necropsy, often it is found that the lungs
are unable to collapse and are tan in color. The kidneys may have white streaks or spots.
Pigs with PMWS may also experience enlargement of several lymph nodes, including
mesenteric, mediastinal, and superficial inguinal (Gillespie et al., 2009).
In addition to the presence of lesions and other clinical signs, PMWS can alter
cytokine expression in infected pigs. The disease causes an over-expression of interleukin
10 (IL-10) in the thymus, which can lead to thymic depletion as well as atrophy in the
thymus. Also, PMWS increases the expression of interferon-gamma (IFN-γ) in the tonsils
(Darwich et al., 2003). In the study Darwich and others published, they used 10 eightweek old piglets that were showing signs of wasting and respiratory disorder. Three pigs
had such severe thymic atrophy that their thymus could not be found at necropsy. In the
other seven pigs, enlargement of the lymph nodes, interstitial pneumonia, and
lymphoplasmacytic hepatitis were observed. Histological lesions had mild to severe
lymphocyte depletion. In addition, a marked increase in IL-10 was observed. Interleukin10 is responsible for having an anti-inflammatory effect in the body, and also regulates
natural killer and B-cell growth; thus, an increase in IL-10 indicates the presence of an
active immune stressor. Another observation from the study was a decrease in IL-2 and
IL-12 in the spleen, likely due to extensive T-cell damage.
Development of PMWS depends on numerous factors. Sows vaccinated against
PCV2 can protect piglets via passive immunity. Experimental infections by Tomas et al.
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in 2008 indicated that piglets that did not receive colostrum from sows had a higher
incidence of PMWS. A study by Calsamiglia et al. in 2007 also demonstrated that piglets
born to sows with low maternal antibodies had higher mortality rates than piglets born to
sows with higher antibody titers. In addition, it was found that sows with high PCV2
viremia had higher piglet mortality rates (Grau-Roma et al., 2010). Also, management
flaws such as drafts, overcrowding, mixing ages of pigs, and deficient air quality can
worsen PMWS conditions (Harding and Clark, 1997). Post-weaning multisystemic
wasting syndrome is known as multifactorial; PCV2 is needed for development of the
disease, but infection with PCV2 is not necessarily enough to create a clinical condition
(Calsamiglia et al., 2007).
In addition to sow immune status, another factor affecting PMWS development is
virulence of the infecting strain. Numerous studies have confirmed that PCV2b is the
strain most common in natural infections with PCV2 (Grau-Roma et al., 2010). Infection
with PCV2a has been demonstrated to be associated with non-PMWS-affected farms
(Carman et al., 2008; Grau-Roma et al., 2008). Therefore, the virulence of PCV2a is
considered to be lower than the virulence of PCV2b.
In 2000, Sorden determined a definition of PMWS in which all factors must be
present for accurate diagnosis. These factors included: presence of clinical symptoms
such as weight loss, respiratory disease, and wasting; also, the presence of PCV2associated lesions, which includes lymphoid depletion or histiocytic replacement of
follicles in lymphoid tissues; and, the presence of PCV2 antigen or nucleic acid as
determined by immunohistochemistry (Opriessnig et al., 2007).
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In order for a complete and accurate diagnosis of PMWS, formalin-fixed tissue
samples should be submitted for testing. Portions of the lung work best for diagnosis;
other suitable tissues include lymphoid tissues (tonsil, thymus, spleen), pancreas, liver,
and kidney. Fresh samples may be used to rule out the presence of other pathogens,
including fresh lung, tonsil, and spleen (Sorden, 2000). In their paper, Opriessnig and
others (2004b) explained a scoring system of seven lymphoid tissues to determine the
extent of PCV2 infection. These tissues included: superficial inguinal, external iliac,
mediastinal, tracheobronchial, and mesenteric lymph nodes; spleen; and tonsil. The
scoring system ranged from zero to three for the categories of lymphoid depletion,
granulomatous inflammation score, and PCV2-immunohistochemical score. This system
enabled a subjective but consistent evaluation of tissues affected by infection.
There seem to be no herds safe from a PMWS outbreak. The disease can affect
farrow-to-finish, farrow-to-feeder, off-site nursery, and grower pig operations. It has been
found in small operations with as little as 50 sows and large operations with as many as
1200 sows (Harding and Clark, 1997).
Because many PCV2 cases experienced co-infection, it was postulated that
various pathogens may use the same mechanism to evade the immune system. Another
idea is that infection with PCV2 may make pigs more susceptible to the acquisition of
other pathogens. Infection with PCV2 and other viruses simultaneously, such as porcine
parvovirus or PRRSV, may perpetuate the effects of the virus (Krakowka et al., 2000).
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PCV2-associated Enteritis
Porcine circovirus 2-associated enteritis is not as well reported but can have
effects on many systems in the body. Pigs with the disease experience diarrhea and
inflammation of the colon (Kim et al., 2004a). The diarrhea starts out yellowish in color
and progresses to black. Piglets with PCV2-associated enteritis go through periods of
decreased weight gains. The disease manifests itself in pigs between 40 and 70d old
(Chae, 2005).
Enteritis caused by PCV2 infection is another PCV associated disease. In a
scenario described by Kim et al. (2004a), 150 Landrace x Large White sows experienced
an outbreak of PCV2 induced enteritis, where 30% of the piglets developed diarrhea
symptoms within a 3-week period. The diarrhea was non-responsive to antibiotic
treatment. Two pigs were selected from the herd and sent to a diagnostic laboratory for
necropsy. Two more pigs were selected from two other herds and submitted. The pigs
were euthanized and samples of lung, heart, inguinal lymph node, tonsil, thymus, spleen,
intestines, liver, kidney, and pancreas were collected, formalin-fixed and paraffinembedded. Both small and large intestines were observed for the presence of several viral
pathogens including PCV2, PPV, PRRSV, and classical swine fever virus (CSFV).
The pigs consistently demonstrated granulomatous inflammation and lymphoid
depletion in the Peyer’s patches in both the large and small intestines. Two of the pigs
suffered from multifocal necrosis and ulceration with fibrin in both the cecum and colon.
PCV2 was isolated from the lymph nodes of two of the pigs as well. A hybridization
signal for PCV2 was found in Peyer’s patches from the six pigs. The scientists found,
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using in situ hybridization, that PCV2 replicated inside the macrophages of the Peyer’s
patches.
Diagnosis criteria of PCV2-associated enteritis include three factors. First, the
pigs must be suffering from clinical signs of diarrhea; next, the Peyer’s patches must
contain those lesions consistent with PCV2 infection, but the lesions must NOT be
present in the lymph nodes; last, lesions in the Peyer’s patches must contain traces of
PCV2 (Chae, 2005). Diagnosis of the disease can create difficulty because the symptoms
are similar both clinically and histopathologically to PMWS. The general rule is that if
lesions are observed in the lymph node, the pig suffers from PMWS; lesions in the
Peyer’s patches are due to PCV2-associated enteritis (Kim et al., 2004a).

Porcine Respiratory Disease Complex
Porcine respiratory disease complex (PRDC) clinically affects pigs around 16 to
22 weeks of age. Symptoms of the disease include retarded growth, lower feed
efficiencies, anorexia, cough, and shortness of breath (Kim et al., 2003). An increase in
mortality due to either single or multiple bacterial infections characterizes the disease
complex (Chae, 2005). Pneumonia caused by PRDC can be due to both bacterial and
viral pathogens. Co-infection with PCV2 and other viruses such as PRRSV, swine
influenza virus, or Mycoplasma hyopneumoniae can intensify the clinical symptoms of
the disease. For instance, co-infection with PCV2 and porcine parvovirus can produce
severe lesions (Kim et al., 2003). In addition, experimental evidence suggests that a
synergy between PCV2 and PRRSV exists (Chae, 2005).
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In a study done by Kim and others in 2003, the results illustrated that PCV2 is
common in pigs that suffer from PRDC. Eighty-five pigs out of 105 showed positive cells
for PCV2, and 43 of the 85 pigs illustrated co-infection by PCV2, PRRSV, and porcine
parvovirus (PPV) together. PCV2 was tested by in situ hybridization and consistently
showed up in the lung lesions, which may mean that PCV2 plays an integral role in the
development of PRDC (Kim et al., 2003).
Porcine respiratory disease complex generally elicits similar symptoms to PMWS.
However, PRDC usually occurs in older pigs (16 to 22 weeks) as compared to PMWS (8
to 16 weeks of age). PRDC caused by PCV2 also has several specific histological signs,
including widespread granulomatous inflammation, multinucleated cells, and
intracytoplasmic basophilic viral inclusion bodies (Kim et al., 2003). And, PCV2
consistently causes lesions that demonstrate bronchointerstitial pneumonia with
peribronchial and peribronchiolar fibrosis (Chae, 2005).
Specific criteria have been established in order to diagnose the presence of PCV2
as the cause of the disease complex. First, there must be the presence of respiratory
symptoms that do not respond to antibiotic treatments. Next, the pig must have presence
of pulmonary lesions; also, PCV2 must be present in the lesions. Last, the pig must not
have the characteristic lesions associated with PMWS. If a pig meets all four criteria,
PCV2 infection status is the confirmed cause of PRDC (Chae, 2005).

PCV2-associated Reproductive Failure
The first report of reproductive failure associated with PCV2 viral DNA surfaced
in Canada in 1999 (Gillespie et al., 2009). Clinical signs from commercial farms showing
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infection of PCV2 include higher incidence of abortions, stillbirths, and delivery of fetal
mummies. Several studies conducted in the early 2000s and reported in a review paper by
Chae in 2005 indicate that infection of the dam with PCV2 can lead to stillborn near-term
fetuses and premature piglets.
Sanchez and others in 2001 determined that PCV2-associated reproduction
problems can occur throughout all phases of gestation. In addition to infection of the
dam, it has been demonstrated that PCV2 can be shed in semen of an infected boar. In a
study by Larochelle and others, four boars were intra-nasally infected with two
concentrations of PCV2 isolate LHVA-V53. The boars were housed singularly and
semen was collected 10 times after infection with the virus. In addition, serum samples
were taken eleven times to test for the presence of PCV2. It was found that the boars all
recurrently shed PCV2 DNA in their semen. However, it was not determined if the PCV2
DNA was infectious, and the authors suggested that follow-up studies should be
conducted to find out if PCV2 shed in the semen could induce infection in sows that were
either naturally mated to infected boars, or sows that were artificially inseminated with
infectious semen (Larochelle et al., 2000).
A study conducted by Kim and others (2004b) used 350 aborted and stillborn
fetuses from 321 Korean farms to test for the incidence of PCV2, porcine parvovirus, and
porcine respiratory and reproductive syndrome. Forty-three percent of the piglets that
underwent reproductive complications tested positive for a least one of the three viruses.
A total of 35 of the 350 cases tested positive for PCV2 alone. This study promoted the
idea that PCV2-associated lung lesions are not always present in aborted fetuses. Of 12
fetuses that were aborted in late gestation, only four exhibited lesions. Two of six
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stillborn piglets showed lesions as well. The lesions that were present were found in
varying locations, and were moderately severe. The authors suggested that PCV2 might
be able to induce reproductive failure in all stages of gestation- early, middle, and late.
O’Connor et al. (2001) described an outbreak at a 3,000-sow farm where acute
reproductive losses were experienced. The rate of mummified fetuses rose to almost 15%
during an 8-week period. In addition, the rate of stillborns and pre-weaning mortality hit
highs of 8% and 11%, respectively, for that same 8-week period. Piglets from about 40
litters were sent to necropsy labs, where myocarditis and myocardial necrosis were found.
Immunohistochemical staining exposed high amounts of PCV2 antigen in myocardial
lesions in six of the piglets sent to necropsy. Samples from two stillborn piglets and two
that died soon after birth were submitted and tested for presence of PCV2. The virus was
found in the hearts of two piglets and in the pooled lung and splenic tissues of the other
two. This study demonstrated that PCV2 could undergo vertical transmission and infects
piglets in utero.
Park and others in 2004 described a study where six pregnant sows were infected
with a strain of PCV2 isolated from an aborted fetus. Two sows remained uninfected as
controls. The six infected sows delivered a total of 65 stillborn and 10 liveborn piglets,
while the control pigs delivered a total of 18 liveborn piglets and no stillborns. Mild
pneumonia was discovered in 15 of the stillborn, and five of the liveborn pigs that came
from infected sows. The authors proposed that PCV2 may be able to infect sows and then
cross the placenta to infect the piglets. Also, it was demonstrated that PCV2 could
replicate in fetuses after intra-fetal infection.
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Porcine Dermatitis and Nephropathy Syndrome
Porcine dermatitis and nephropathy syndrome (PDNS) was first discovered in
1993 in the United Kingdom (Gillespie et al., 2009). The disease syndrome typically
affects nursery and pigs in the grow-finish stage. However, PDNS has been described in
finishing pigs and replacement gilts as well (Chae, 2005). Clinical signs of PDNS include
fever, lethargic behavior, and occasionally loss of appetite (Harding, 2004). In addition to
these signs, there are often physical manifestations of the disease. Red-purple skin lesions
may arise in several locations, first starting in the hindquarters, limbs, and abdomen
(Harding, 2004). These lesions usually progress to scabs containing black centers and are
located on the rear legs (Gillespie et al., 2009). In addition to visual clinical signs, pigs
experiencing PDNS often have enlarged, pale kidneys with hemorrhages (Harding,
2004). Other gross lesions include edema, enlarged lymph nodes, and gastric ulcerations
(Drolet et. al, 1999). Pigs showing signs of anorexia, weight loss, and skin lesions
combined usually die quickly; mortality rates in pigs showing a multitude of symptoms
can reach 20% (Chae, 2005).
Porcine dermatitis and nephropathy syndrome is a vascular disease, with the
primary lesion being a systemic necrotizing vasculitis. Lesions associated with PDNS
mirror effects of immune complex-mediated disorders that have the ability to commence
an acute inflammation (Drolet et. al, 1999).
The association between PDNS and PCV2 was recognized in 2000 (Opriessnig et
al., 2007). Although PDNS has commonly been associated with PCV2, it remains unclear
whether PCV2 is the only virus capable of causing the syndrome. In a study described by
a review by Gillespie et al. in 2009, Krakowka and others in 2008 found that PDNS was
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isolated from pigs infected with PRRSV and TTV, but these pigs were PCV2-free.
Another study by Wellenberg et al. (2004) looked at three pigs from each of 10 Dutch
herds showing clinical signs of PDNS. The pigs demonstrated fever, lethargy, and were
affected by skin lesions on several locations of the body. Upon necropsy, the pigs
exhibited enlarged grey-brown kidneys with white spots on the renal cortex, as well as
hemorrhagic lymph nodes. It was found that 100% of the pigs contained PCV2 DNA. In
addition, 33% of the pigs tested positive for PPV and 83% of the pigs tested positive for
PRRSV. Therefore, although it is known that PDNS is immune-mediated, there has been
no conclusive evidence that it is related only to PCV2, and that PCV2 is the main cause
of PDNS.
A study by Sipos and others (2005) observed the changes in cytokine levels in
five pigs known to have PDNS, five pigs known to have PMWS, and five controls. In the
PDNS pigs, amounts of the cytokines interleukin 1α (IL-1α), interleukin 6 (IL-6), and
interleukin 10 (IL-10) were significantly greater than in the controls. This was likely due
to an inflammatory response against the pathogen. In addition, interferon gamma (IFN-γ)
levels were markedly greater (approximately two-fold) than in controls. The authors
concluded that this may imply that cytotoxic T cells were important at this stage of
infection. Lastly, levels of interleukin 2 (IL-2) and interleukin 4 (IL-4) both decreased.
Since both are found in leukocytes, this could be due to a decrease in the amount of
overall leukocytes.
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Diagnosis
The presence of clinical signs has thus far been the most straightforward way to
diagnose PCV2. Characteristics of PWMS, PDNS, and PRDC are generally recognizable
on farms and in herds. Other associated diseases can be determined by various lab
procedures. If PCV2 antigen is contained in more than one lymphoid tissue, or a
lymphoid tissue and an organ system such as the kidney or lung, it is generally regarded
that PCV2 is present in the body in an infectious capacity. Chronic severe PCV2 is
demonstrated by severe lesions even in the presence of only limited PCV2 antigen
content (Gillespie et al., 2009).
Immunohistochemistry (IHC) and in situ hybridization (ISH) are methods that
have been established to recognize PCV2. Both tests use tissues from the animal that
must first be paraffin-embedded and formalin-fixed. The IHC method utilizes both
polyclonal antisera and monoclonal antibodies to detect presence of PCV2, and is a rapid
process with quicker results than ISH. However, a study conducted by McNeilly et al. in
1999 and discussed in a review by Sorden, 2000, suggested that ISH has the ability to
detect more positive cells than immunohistochemistry.
Both virus isolation and polymerase chain reaction (PCR) can be utilized to
identify the presence of PCV2. Virus isolation is not as sensitive as immunohistochemistry or in situ hybridization, but is useful for the production of vaccines for
further research. Using PCR, one can successfully detect between PCV1 and PCV2.
However, it is a method that can easily incur contamination and show false positives.
Sorden (2000) points out that PCR may be too sensitive a test to determine an accurate
PMWS diagnosis. And because most pigs experience PCV2 infection at some point in
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their lives, and PCR can pick up as little as one genomic copy, sensitivity is further an
issue (Opriessnig et al., 2007).
Serology can be used to detect exposure to the virus using a test that can be
performed on large numbers of pigs at once. Modes of serologic testing include indirect
fluorescent antibody assays (IFA), immunoperoxidase monolayer assay (IPMA), enzymelinked immunosorbent assay (ELISA), and a serum-virus neutralization assay. An IFA is
subjective and is not automated. An IPMA is also subjective in terms of endpoints, and is
not automated as well. The ELISA is sensitive and can aid in determination of when the
infection occurs by comparing immunoglobulin G and immunoglobulin M levels. Last,
the serum-virus neutralization assay requires fluorescent antibody or immunoperoxidase
staining to conclude if viral replication is present (Opriessnig et al., 2007).
Serologic tests are generally used for diagnosis of herds, not individual pigs. Part
of the reason for this is that pigs may be seropositive and not show any clinical symptoms
of PCVAD. This should be taken into consideration when serologic tests are performed
(Gillespie et al., 2009).
Grau-Roma and others, in a 2010 review, mentioned that quantitative real-time
PCR (qPCR) is another method that can be used for determination of infection. Threshold
levels can be set for blood samples or swabs to test for PCV2; these thresholds will differ
from lab to lab and therefore consistency can be a problem. Using live animals limits the
capacity of qPCR, however; there have been issues with specificity and sensitivity, and
whether qPCR can replace histopathological examinations remains to be seen.
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Prevention and Control
No treatment practices have been developed to combat PCV2 infection thus far.
Because there is a wide variety of symptoms and range of reactions to infection, it had
been a challenge to formulate a catchall procedure. Prognosis upon exposure to PCV2
relies on many factors, including immune status, age at infection, and specific syndrome
that is manifested.
Prevention practices are also variable and inconsistent. Even the farm with the
strictest vaccination and sanitation protocols can experience an outbreak. Prevention of
co-infections by vaccinating for other bacteria and viruses can help avert the spread of
PCV2, but this becomes impractical when so many co-infectious agents exist.
Disinfection to thwart PCV2 outbreaks is critical in large farms and research
settings. In their 2007 review, Opriessnig and others discussed several methods of
reducing viral replication. These methods, tested in laboratory settings, include: sodium
hydroxide, Virkon S (Antec International, UK), Roccal D Plus (Parmacia and Upjohn,
US), Clorox Bleach (Clorox Company, US), and Tex-Trol (Bio-Tek Industries Inc, US).
Although not tested in commercial settings, these disinfectants have been successful in
inhibition of the spread of PCV2, when used according to manufacturer’s directions.
Deterrence of PCV2 infection involves many basic strategies that farms may
already have in place. Adequate housing management is a vital factor in the prevention of
PCV2. Reduction of stress on the animals, proper hygiene of employees, and the use of
an all in/all out strategy can reduce the risk of PCV2 contraction (Gillespie et al., 2009).
In 2000, Madec and others devised a strategy known as ‘Madec’s 20-point plan’ to
combat the spread of PCV2. Their plan included procedures such as limited animal
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contact, proper disinfection, and the isolation or euthanasia of disease pigs in the herd.
Harding in 2004 also suggested that maintenance of ideal pen stocking density and
segregation of pigs by age could decrease the spread of PCV2.
In addition, a list of factors that could decrease the risk of PMWS was discussed
in Grau-Roma et al. review (2010). These factors include: separate flush pits for separate
rooms of pigs, shower facilities for employees, sorting pigs by sex at the nursery stage,
vaccination of sows against atrophic rhinitis, use of oxytocin during farrowing, and use of
spray-dried plasma in nursery rations. Also outlined was a list of practices that might
increase the incidence of PMWS, including: high levels of cross-fostering, large range in
weight and age entering the nursery, and vaccination of gilts against PRRSV.

Vaccinations
Several vaccines have been developed to stop the progression of PCV2 associated
diseases. The first vaccine, Circovac® by Merial, was approved for use in 2007. Since
then, the FDA has approved four more vaccines for use in the United States.
Circovac® is a killed-PCV2 virus vaccine for sows that uses mineral oil as the
adjuvant. The drug requires 2 mL intramuscular injections about three to four weeks apart
at least two weeks before mating. A booster vaccine once every gestation period, at least
two to four weeks before farrowing is scheduled, is also required. The drug is available
for purchase in both Canada and Europe (Iowa State website).
Circumvent™ PCV by Intervet is an inactivated Baculovirus that uses two mL
intramuscular injections three weeks apart. The vaccine is designed for healthy pigs three
weeks or older and is sold in the United States and in Canada (Iowa State website).
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Another vaccine by Intervet, Porcilis® PCV, is a PCV2 capsid that is designed for piglets
as well, and is delivered with a Diluvac Tocopherol adjuvant. It also requires two
injections (Burch, 2008).
Suvaxyn PCV2® One Dose was developed for healthy pigs four weeks or older.
The vaccine is available in the United States, and is an inactivated PCV1-2 chimera. The
vaccine is marketed by Fort Dodge® Animal Health (Iowa State website). It is developed
with SL-CD aqueous as an adjuvant (Burch, 2008).
Last, Ingelvac® CircoFLEX™ is PCV2 expressed in inactivated Baculovirus and
is delivered in a single dose of one mL intramuscularly. It is designed for piglets three
weeks of age and older, and is marketed in United States by Boehringer Ingelheim (Iowa
State website).
Numerous studies have been carried out to determine the efficacy of these
vaccines since their approval in the past years. One such study was performed by Lyoo
and others (2010) and tested the use of Circumvent™ PCV, Ingelvac® CircoFLEX™, and
Suvaxyn PCV2®. Four pigs from 20 litters in a natural farm setting were selected and
assigned one of the above doses, with the fourth pig remaining as a control. All pigs were
vaccinated using the protocols as established by their respective companies. It was
determined that the three vaccine groups differed in average daily gain (ADG), in which
the pigs receiving the Circumvent™ PCV and Ingelvac® CircoFLEX™ vaccines had
higher ADG than control pigs (P < 0.05). In terms of viremia, only 16.9% of the pigs
vaccinated with Circumvent™ PCV tested positive for PCV2 DNA; 18.1% of the
Ingelvac® CircoFLEX™ pigs tested positive; and 15.2% of the Suvaxyn PCV2® pigs
tested positive. Although they had PCV2 DNA, they demonstrated no clinical symptoms.
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Another study by Takahagi et al. (2009) tested two vaccines, Porcilis® PCV and
Ingelvac® CircoFLEX™, according to their manufacturer regulations. A third group was
not vaccinated and used as controls. A total of 997 pigs were used. It was found that at 24
weeks, the mortality rate of the Porcilis® PCV-vaccinated pigs was 11%; for Ingelvac®
CircoFLEX™, the mortality rate was 13%; and for the controls, the mortality rate was
32%. Mortality rates were drastically reduced after vaccination and therefore use of a
vaccination against PCV2 is a viable option to reduce the incidence of PCV2 associated
diseases.
Although vaccines for PCV2 are relatively new to producers and scientists, they
seem to be capable of decreasing infection and mortality rates and also increasing ADG.
Further testing is needed to completely understand the mechanisms and full effects of the
vaccines.

Genetic Parameters for Selection
Although there is no infallible method for treatment or prevention of PCV2
infection, it may be possible to select for animals with an increased resistance to PCV2.
In a dissertation by Bates in 2008, a selection experiment was carried out to estimate
genetic and environmental effects of PCVAD. The extensive study involved 3,271 pigs
from two genetic lines. The lines had been selected over many generations for increased
reproduction rates and growth. All pigs were transported to one of four locations, which
included confinement buildings and outdoor lots. The pigs were scored for symptoms of
PCVAD, including muscle wasting, slowed growth respiratory issues, and diarrhea.
These scorings were performed approximately every seven to 10 days. Pigs receiving a
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score of 0 displayed no symptoms and were considered normal. Pigs receiving a one
score had minor symptoms and were thought of as potential PCVAD pigs. Pigs with a
two score had obvious signs of PCV2 infection. Pigs receiving a two were sent to
necropsy, and immunohistochemistry and real-time PCR was performed. All pigs tested
negative for PRRSV, but co-infection with M. hyopneumoniae was found in 19 pigs.
Eighteen pigs experienced a co-infection with Streptococcus suis, and four also had
Lawsonia intracellularis.
Once the data were analyzed, several significant correlations and heritabilities
were estimated. The PCVAD scores were compared with weights at birth weight,
weaning weight, d65 weight, and d180 weight. It was found that birth weight and
PCVAD score had a moderate positive correlation (r = 0.34, P < 0.10). Also, d65 weight
had a strong negative correlation with PCVAD score (r = -0.53, P < 0.01). It was found
that IgG levels at d90 were strongly negatively correlated with PCVAD score
(r = -0/67, P < 0.001). In terms of direct heritability, PCVAD score had a low direct
heritability (0.16 +/- 0.04). Birth weight had a moderate heritability (0.27 +/- 0.07). The
heritability of weaning weight was 0.16 +/- 0.06, and that of both d65 weight and d180
weight was 0.23 +/- 0.06.
There were also differences in weights at all time points. At birth, pigs with a
PCVAD score of 0 differed from those with a score of 1 by 0.10 kg. At weaning, the
difference was 0.51; at d65, the difference was 3.0; at d180, the difference was 20.9
(all P < 0.001). This provided significant evidence that infection with PCV2 diminishes
weight gain, and the problem is exponentially worse the longer the pig is alive.
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The author suggested that a selection index could be utilized to lower the
occurrence of PCV2 infection. An index using estimated breeding values (EBV) for traits
such as PCVAD score and weight could accomplish this. If a pig having low weight at
d180 and had a positive PCVAD score, this pig could be excluded from the breeding
herd.
Bates discussed that selection could help in populations where PCV2 infection
was consistently high. Although vaccinations appear to help control the spread of the
virus, they can be costly to producers. Also, every pig must be vaccinated in order to gain
protection against the virus. Using selection to control disease spread is an alternative that
would not raise costs significantly to the producer. Selection against PCVAD is reliant on
exposure to the virus. A pig must receive maternal antibodies, and it turn have them
wane, to come into contact with the virus. Therefore, selection for PCVAD resistance is
dependent on exposure to PCV2.

Summary
Porcine Circovirus 2 is a complex disease with no current treatment regime.
While the complete pathology of the virus is not understood, steps can be taken to
prevent outbreaks of the diseases that the virus causes. Vaccines are available but at a
high cost to producers, so it is becoming increasingly evident that an alternative is
needed. Genetic selection for disease resistance may become the best option for
decreasing the prevalence of PCVAD. Because a definite difference in susceptibility of
certain breeds exists, selection of candidates for reproduction can be used to decrease the
incidence of PCV2. Because of the high economic impact of viral pathogens in swine
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herds, genetic resistance is becoming more important as a mechanism to stop the spread
of infectious diseases such as PCV2.
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CHAPTER 2: Variation in Response to Both Natural and Experimental Infection
with Porcine Circovirus 2b

2.1 INTRODUCTION

Porcine circovirus 2 (PCV2) has caused economical problems for producers and
other members of the swine industry since its discovery in 1996. Infection with PCV2
can cause a host of other diseases known as PCV2 associated diseases (PCVAD).
Diseases associated with PCV2 infection elicit a variety of symptoms. The largest losses
from PCV2 infection have occurred following diagnosis of post-weaning multisystemic
wasting syndrome, PMWS, which is characterized by an inability to gain weight creating
a wasting condition, as well as jaundice and lymphocytic depletion (Gagnon et al., 2008).
Another diseases caused by PCV2 infection include PCV2-associated enteritis, which
causes diarrhea and inflammation of the colon (Kim et al., 2004). Porcine Respiratory
Disease Complex elicits retarded growth, lower feed efficiencies, and coughing, and is
known to be at least partially associated with PCV2 (Kim et al., 2003). PCV2-associated
reproductive failure, causing abortion and stillborns; and porcine dermatitis and
nephropathy syndrome (PDNS), which elicits fever, lethargy, and skin lesions (Harding,
2004). All of these symptoms cause unfit pigs that do not grow enough to reach their
genetic potential.
Because there is no treatment for PCV2 infection, it is important to find
alternative methods to stop the virus. Management practices and preventative measures
have been introduced and in some cases implicated, but have not been successful in
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complete eradication of the virus. Vaccines have been proven effective in several studies
(Lyoo et al., 2010; Takahagi et al., 2009). Although they can efficiently prevent the
spread of PCV2, vaccines also raise costs for producers and therefore put a strain on the
industry.
The studies reported here investigated individual responses to both natural and
experimental infections with PCV2 in pigs of two crossbred lines. The data were used to
compare the two genetic lines and understand susceptibility differences between them.
The objectives were to identify pigs with varying patterns of immune response and to
determine if there were differences in other measurable traits, including growth, antibody
level, and viremia. Another goal was to ascertain what components determine why some
pigs show clinical signs and others do not. These studies represent preliminary efforts to
establish a large database of tissues, blood samples, and phenotypes from infected
animals in order to understand the factors that cause variation in immune responses to
PCV2.
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2.2 MATERIALS AND METHODS

2.2.1 TRIAL 1

Animals: All procedures using animals were reviewed and approved by the Institutional
Animal Care and Use Committee at the University of Nebraska-Lincoln. A composite
Large White x Landrace cross selected for 29 generations for increased litter size and
lean growth rate (Line 2, n = 166 representing 41 litters) and a control line with a similar
genetic background (Line 16, n = 63, 16 litters) were used. Pigs were sired by a total of
25 boars. Pigs were farrowed at the University Swine Farm located in Mead, Nebraska,
where routine testing for major pathogens occurs. All pigs were known to be free of
porcine reproductive and respiratory syndrome virus (PRRSV). Following weaning at 21
days of age, 229 randomly-selected pigs of both sexes were transferred to a finishing barn
at the Haskell Agriculture Laboratory in Concord, Nebraska. Pigs were placed randomly
into 16 pens within one room. Pigs selected for the study were not vaccinated for PCV2;
however, their dams were. All pigs were allowed ad libitum access to a standard,
balanced diet supplied by a commercial feed mill.

Serology: Blood samples were collected on d14, d49, and at necropsy. The blood was
collected in 7.5 mL BD Vacutainer tubes (Reference #367987, Franklin Lakes, New
Jersey, USA). After collection, the samples were refrigerated until they could be
centrifuged at 3500 rpm for 15 minutes at 4°C. The serum was poured off into 1.5 mL
tubes for storage and the red blood cells remaining in the tube were discarded. Serum
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samples were tested for the presence of PCV2–IgG and IgM using ELISA (Ingezim,
Madrid, Spain). Samples were considered positive for IgG if the calculated sample-topositive ratio was greater than 0.4. Samples were considered positive for IgM if the
calculated sample-to-positive ratio was greater than 0.3.
The initial objective of the trial was to uniformly infect the pigs on the same day
once maternal antibodies had waned. After infection, the plan was to monitor responses
in viremia, immunoglobulin levels, and weight gain. However, it was found after the
second bleeding that the pigs had already been exposed to the virus. The first sign of this
was some of pigs showing clinical signs of PCV2 infection, including wasting and rough
hair coats. This was determined by the IgM and IgG levels in the serum, as well as viral
copy counts, collected at d 49. Because natural infection had occurred, the decision was
made to not infect the pigs and to perform necropsy on all pigs as soon as possible.

Clinical Evaluation and Necropsy: Pigs were weighed at move-in (d0), d14, and d49.
Necropsy was performed on four days because pigs were transported to the UNL Animal
Science facility where necropsies were performed. Therefore, necropsy was performed
with 63 pigs on d62, 59 pigs on d63, 54 pigs on d66, and 41 pigs on d69 of the
experiment. Samples of spleen, lung, and mesenteric and bronchial lymph nodes were
collected at necropsy. Half of each sample was snap-frozen in liquid nitrogen for future
gene expression analyses and the other half preserved in formalin for histological
examination.
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PCV2 Quantification: Viral DNA was extracted from blood samples using the QIAamp
DNA Minikit (Qiagen, Valencia, California, USA). DNA extracts were used for
quantitative real time PCR quantification (qRT-PCR) and sequencing of PCV2 genomic
DNA. Two pairs of primers were used for amplification of the PCV2b genome. The PCR
was performed using GoTaq Flexi DNA Polymerase (Promega, Madison, Wisconsin,
USA) and standard protocols. Products from the PCR were purified using ExoSAP-IT
(USB Corporation, Santa Clara, California, USA) and sequenced from both directions
using dye terminators on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems,
Carlsbad, California, USA). A list of primers and probes used for both qRT-PCR and
sequencing of the PCV2 genomic DNA is included in Table 1. BioEdit software (Ibis
Therapeutics, Carlsbad, California, USA) was used to assemble and analyze the
sequences.

Genotyping: A total of 110 pigs were genotyped using the PorcineSNP60 BeadChip by
Illumina Inc. (San Diego, California, USA). These pigs were selected using SAS PROC
PRINCOMP, principal component analysis, a multivariate method to look at relationships
among many variables. The principal component analysis indexes animals based on the
score given by the analysis, and the top 55 and bottom 55 were selected for genotyping.
The PorcineSNP60 chip has both allelic-specific primer extension and single-base
extension. The assay is based on direct hybridization of the whole genome-amplified
DNA to a bead array of 50-mer specific probes. Once attached to the probe, the beads are
pooled, arrayed randomly, and assembled into the wells of the slide. The hybridization of
probe to DNA is followed by an enzymatic-based extension assay using DNA
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polymerase and labeled nucleotides. The labels are stained and each single nucleotide
polymorphism (SNP) is then scored.

Sequence Analysis and Alignment: The viral DNA was isolated from ten individuals
showing signs of disease and sequenced. Sequencing was performed from both directions
using dye terminators on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems).
This sequence, which matched in each individual, was aligned and entered into BLAST
(Basic Local Alignment Search Tool) to find the PCV2b strain with the highest sequence
identity.

Statistical Analysis: Correlations among variables (IgG, IgM, weight changes, and
viremia) were estimated using PROC CORR of SAS software (SAS Institute Inc., Cary,
North Carolina, USA). No fixed effects were included in the model.
The genotypes of each SNP were analyzed using GenCall Data Analysis Software
(Illumina, San Diego, California, USA). Each SNP genotype was given a GenCall Score
to sort out failed genotypes, DNA, or loci. This GenCall Score is based on the reliability
of the SNP assay, DNA, or ability of a genotype call to cluster in genotype groups. The
data was analyzed using JMP software (SAS, Cary, North Carolina, USA) and sorted by
SNP position. This information was used to make overlay plots for both minor allelic
frequency and Hardy-Weinberg Chi Square tests for both Trial 1 and Trial 2.
Gene associations were made using ASREML software (VCN International,
Hemel Hempstead, United Kingdom). The software is a statistical package to fit linear
mixed models using restricted maximum likelihood to fit large data sets. Each SNP from
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BeadArray was assessed for association with PCVAD phenotypes using the ASREML
package, with pen as a random effect, genotype as a fixed effect, and based on an
extensive pedigree over six generations. Additive and dominance effects as well as an F
value for each SNP were estimated. A false discovery rate was estimated for additive and
dominance effects for every marker. Following analysis in ASREML, the data was
entered into JMP for the creation of Manhattan plots to illustrate the genome-wide
association studies.

2.2.2 TRIAL 2

Animals: All procedures using animals were reviewed and approved by the Institutional
Animal Care and Use Committee at the University of Nebraska-Lincoln. The experiment
included 91 crossbred barrows from 24 litters. Pigs were either a two-way cross of Large
White and Landrace (W x R, n = 72) or three-way crosses produced by mating Duroc
sires with Large White x Landrace sows [D (W x R), n = 19]. Pigs were farrowed at the
University of Nebraska Swine Farm in Mead, Nebraska, where routine testing for major
pathogens occurs. All pigs were known to be free of porcine reproductive and respiratory
syndrome virus (PRRSV). Pigs selected for the study were not vaccinated for PCV2,
although their dams were.
At approximately 35 days of age, the pigs were moved to the Animal Science
research facility for the infection experiment. The barrows were housed in one room of
the building and randomly assigned into one of 18 identical pens. The pens contained a
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combination of slatted and solid surface flooring. The pens allowed each pig
approximately 0.65 m2 of floor space, which exceeds standard space requirements for
pigs of that age. All pigs were allowed ad libitum access to a standard, balanced diet
manufactured at the ARDC feed mill.

Experimental Infection: The objective was to infect pigs with PCV2b virus after
protection from maternal antibodies had waned. Another factor in the timing of the
infection was to infect as soon as possible because of the threat of a natural infection.
Blood was drawn from pigs at the University Swine Farm in Mead, Nebraska, before the
pigs were transported to the Animal Science facility. The blood was analyzed for
immunoglobulin G (IgG), which is an indicator of maternal antibodies, using an ELISA
(Ingezim, Madrid, Spain). The sample-to-positive ratio of IgG in all individuals selected
for the experimental infection was less than 0.3 at the time of inoculation. This level is
specified by Ingezim as negative for antibodies. In addition, immunoglobulin M (IgM)
was tested as an indicator of self-antibodies produced in response to infection. Sample-topositive ratio was less than 0.4, the cut-off recommended by Ingezim, showing that
natural infection had not occurred.
The virus inoculum contained the titer of 104.0 50% tissue culture infection dose
(TCID50)/mL in minimum essential media with 50 ug/mL gentamicin and 5% fetal calf
serum. The original experimental protocol was to infect each pig with 2 mL of inoculum
intramuscularly (IM) and 3 mL intranasally (IN). However, approximately 20 minutes
after inoculation of 20 pigs, anaphylactic shock occurred in 10 pigs and eight of them
died. Twelve pigs inoculated with 2 mL IM and 3 mL IN survived. The dose
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administered to the remaining pigs was therefore altered. Most of the pigs (n = 58)
received 1 mL IM and 3 mL IN. The rest of the pigs received a variation of this dose: 1
mL IM with 0.5 mL IN (n = 4) or 2 mL IM with 0.5 mL IN (n = 8). The pigs used for
these treatments were chosen at random. Ten pigs were selected as negative controls,
assigned to separate pens, and not inoculated.

PCV2b Isolate: Isolate UNL_VBMS was taken from a pig showing symptoms of
PCV2b infection. Viral DNA was isolated using QIAamp DNA Minikit (Qiagen,
Valencia, California, USA). Two pairs of primers were used to amplify the entire PCV2b
genome. Amplification of DNA was performed using GoTaq Flexi DNA Polymerase
(Promega, Madison, Wisconsin, USA), and PCR products were purified using ExoSAPIT (USB Corporation, Santa Clara, California, USA). Viral DNA was sequenced from
both directions using dye terminators and ABI PRISM 3100 Genetic Analyzer (Applied
Biosystems, Carlsbad, California, USA). Sequence analysis using BLAST revealed that
the strain used for inoculation was most similar to strain FMV-05-6507. This strain was
identified first in Quebec, Canada in 2005 and is known to induce clinical signs of
PMWS and cause an increase in mortality rate.

Serology: Blood samples were collected before inoculation and at 7, 14, 21, and 28 d.p.i.
(days post infection). The blood was collected into sterile 7.5 mL tubes (BD Reference
#6530) and then separated into two tubes: half the blood went into the BD Vacutainer
tubes used in trial 1, and the other half went in 7.5 mL Tempus Blood RNA tubes. These
tubes contain an RNA stabilization solution that must be shaken vigorously once in
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contact with blood, and are manufactured by Applied Biosystems (Carlsbad, California,
USA). The blood in the BD tubes was refrigerated until it could be centrifuged at 3500
rpm for 15 minutes at 4°C to obtain serum. The Tempus tubes were frozen at -20°C for
storage. Levels of PCV2-specific antibodies, IgG and IgM, were measured from serum
using ELISA. Samples were considered positive if the calculated sample-to-positive ratio
was greater than 0.3 for IgG and 0.4 for IgM. Antibody data were normalized based on
positive control values obtained on each plate.

Clinical Evaluation and Necropsy: Pigs were observed daily for clinical signs of
infection, and were weighed at 0, 7, 14, 21, and 28 d.p.i. Necropsy was performed at 28
d.p.i. Lung, spleen, and mesenteric and bronchial lymph nodes were collected for
histological examinations and gene expression analysis.

PCV2 Quantification: Viral DNA was extracted from serum collected at 7, 14, 21, and
28 d.p.i. using QIAamp DNA Minikit. Estimates of viral copy number were obtained by
quantitative real-time PCR using TaqMan Master Mix and ABI7900 (Applied
Biosystems, Carlsbad, California, USA). A list of primers and probes used for both qRTPCR and sequencing of the PCV2 genomic DNA is included in Table 1. The area under
the curve (AUC) was calculated to estimate total viral load throughout the 28-day
experimental infection.

Genotyping: All infected pigs were genotyped using the PorcineSNP60 BeadChip by
Illumia Inc. (San Diego, California, USA). This chip is described in Section 2.2.1.
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Sequence Analysis and Alignment: The PCV2 strain used in experimental infection was
isolated from a pig with PCVAD symptoms, cultured and sequenced. Viral DNA from
four pigs of each IgM group (early, late, and no responders) was sent for sequencing to
confirm that they were infected with the same strain. Sequences were aligned using
Sequencher software (Gene Codes Corporation, Ann Arbor, Michigan, USA). Once
aligned, the sequences were entered into BLAST (Basic Local Alignment Search Tool) to
find the sequence with the highest sequence identity.

Statistical Analysis: Least Squares Means (LSM) were obtained using mixed-model
procedures including the immune response pattern with crossbred lines as fixed effects
and pen and litter as random effects. The variables included in the model were IgG, IgM,
viremia, and ADG at all time points. Analysis of the IgM antibody profiles during the
challenge revealed that infected individuals could be characterized by three patterns of
immune response and could be separated in three groups. Most pigs clearly fitted into one
of these groups, but in some cases pigs were placed in a group based on a subjective
judgment. Correlations among traits were calculated from variances and covariances
adjusted for line effects.
The genotypes of each SNP were analyzed using GenCall Data Analysis Software
as described in Section 2.2.1. This information was used to make overlay plots for both
minor allelic frequency and Hardy-Weinberg Chi-Square tests using the data from both
trials.
Gene associations were made using ASREML software (VCN International,
Hemel Hempstead, United Kingdom) as described in Section 2.2.1. The model included
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pen, litter, and genetic line as random effects, and genotype as a fixed effect. Following
analysis in ASREML, the data were entered into JMP for the creation of Manhattan plots
to illustrate the genome-wide association studies.
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2.3 RESULTS AND DISCUSSION

2.3.1 TRIAL 1

Serology: All pigs used for the challenge came from dams that were vaccinated against
PCV2. The pigs received maternal antibodies, specifically IgG, through colostrum from
the dam during nursing following birth. Results from ELISA indicated that on d14, which
was the first bleeding time point, 23 of 217 pigs (10.6%) were positive for IgG. Because
the pigs were not bled before moving into the facility to check for maternal antibodies, it
was deduced that the differences among pigs was due to the rate of maternal antibody
decay varying from one individual to the next. However, IgG levels were much higher at
d49 with 148 of 217 pigs (68.2%) being positive, indicating that infection had occurred
between these time points and the immune system was mounting a secondary response to
the virus. At necropsy, 198 of 217 pigs (91.2%) had a high enough sample-to-positive
ratio to be considered positive for IgG.
In terms of IgM, a very low percentage of pigs were positive at d14, only two of
217 (0.009%.) Because IgM is a measure of individual primary response to an immune
stressor, it was determined that these pigs were experiencing PCV2 infection. The two
infected pigs were housed in pens two and six. Because so many pigs were serologically
positive for IgM at the next bleeding on d49 (77.4%), it seemed that these two pigs could
have spread the virus throughout their pens and consequently to other pens. This is
possible because the pens that housed the pigs had metal bars with approximately six
inches of distance in between. This was enough room for the pigs to touch snouts
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between the bars. Because nose-to-nose contact is a common mode of transmission, it is
logical to assume that the virus started in two pens and was spread throughout the barn in
a 35-day period. The number of positive pigs was somewhat lower at necropsy (72.4%).
The modest decrease could be due to the fact that some of the pigs had already mounted
an immune response against the virus. Once anti-PCV2 IgM had peaked after infection, it
tended to decline.
This decline in IgM values has been demonstrated in previous studies done by
Opriessnig et al. (2006). PCV2-specific IgM antibodies in the pigs infected with the
strain PCV2-4838 peaked at d21 and began to decline by d28 post-infection. The levels
of IgM in the pigs infected with the strain PCV2-40895 in their study were even higher,
but followed the same declining trend. At necropsy, IgM response had started to drop for
some of the pigs, but remained high for others. Also, new infections could have occurred
between d49 and necropsy, so pigs that had had lower IgM values could have started to
see an increase.

PCV2 DNA in Serum: Real-time quantitative PCR establishment of viral copy counts
indicated that at d14 all pigs were negative for PCV2 viremia. At d49, the second
bleeding, least squares means of all pigs was 3.75 viral DNA copies per mL serum
(log 10) (P < 0.0001 for test of mean greater than 0). At the last bleeding at necropsy,
least squares means for all pigs was 3.58 viral DNA copies per mL serum (log 10)
(P < 0.0001). There were no differences between lines for viremia at any time point
(Figure 1). For area under the curve for viremia, the least squares mean was 127.9 viral
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DNA copies per mL serum (log 10) (P < 0.0001). This statistic helps to explain the entire
viral load that each animal experienced throughout the trial.
These results indicated that there was a steady increase in viremia throughout the
infection period. This also showed that the pigs were unable to mount an adequate
defense against the virus. As more pigs came into contact with the virus, it became
increasingly harder to avoid becoming ill. It seemed that the viral copy counts peaked
somewhere between d49 and necropsy. This sheds a little light on the timing in which the
pigs first contracted the virus. This information can be combined with the fact that IgM
levels spiked from d14, when only two pigs were positive, to d49, when 168 pigs were
positive. Likely, around d49 the highest number of pigs were infected, and the highest
viral copy counts were present in their DNA. Unfortunately, without more frequent
testing, it is impossible to know the exact point of infection for each individual.

Clinical Evaluation: At necropsy, the following clinical signs were observed: evidence
of mycoplasma (n = 14), enlarged mesenteric lymph nodes (n = 10), interstitial
pneumonia (n = 3), enlarged bronchial lymph nodes (n = 2), edema (n = 2), abscesses of
the spleen and liver (n = 2), peritonitis (n = 1), and polyserositis (n = 1). In addition, 12
pigs died before the conclusion of the trial, either in the pens or during the transportation
process to the kill facility. Necropsy could not be performed on these animals.

Genetic Characterization of the PCV2b Isolate: Virus was isolated from ten individuals
showing signs of disease and sequenced. It was established that the source of infection
was a PCV2b strain, and was named UNL_ANSCI. It was found to have three
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nucleotides that differed from the strain being developed for inoculation of the second
round of pigs, Trial 2.

Genotyping: The PorcineSNP60 BeadChip was used to genotype 110 animals from Trial
1, and provides sufficient density in order to identify either markers or groups of markers
that are in association with deviations of physiological traits. There were 62,163 SNPs,
and the low GenCall Score Cutoff was 0.15. The GenCall Score Cutoff is calculated for
each genotype and ranges from zero to one. Because the scores decline when the sample
is further from the center of the cluster when the data point is associated, genotypes with
a Gencall score of less than 0.15 are considered not “quality” and are not given a
genotype. The average call rate of the 110 animals was 99.53%, and the average number
of calls per animal was 59,613. The average number of no calls, in which the genotype
could not be called with accuracy, was 281. The average heterozygosity was 24.9% for
the 110 pigs genotyped.
Figure 2 illustrates overlay plots of minor allelic frequency versus SNP position at
each chromosome for all pigs genotyped in both trials. For example, on SSC 11, between
32 and 41 Mb, the minor allelic frequency of a large number of SNPs is below 0.2. A
similar approach was used to identify a chromosomal region where clusters of SNPs are
in Hardy Weinberg genetic equilibrium (Figure 3). An example of this is on SSC1, at
approximately 14 Mb, where there is a cluster of SNPs. Another cluster on SSC1 is
between 27 and 28 Mb. SSC9 shows a cluster occurring between 60 and 61 Mb. These
plots can be used to discover errors in genotyping methods as well. On SSC1, a SNP at
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17 Mb appears to be informative because of its spread, but is likely due to genotyping
error since it is one data point and not a cluster.
Both approaches can be used to uncover regions of the genome where selection is
affecting the frequency of beneficial alleles by driving them either up or down. Genetic
dissection of this region could uncover functional polymorphisms for traits of economic
importance.

Gene Associations: The software package ASREML was used to determine genomewide associations between the SNP genotypes for the 110 pigs genotyped and PCV2specific traits- IgM, IgG, viremia, and ADG.

Correlations: There was a moderate positive correlation between the changes in weight
from d1 to d14 with IgG at d49 (0.24, P < 0.05). Another positive correlation existed
between change in weight from d1 to d14 and IgG at necropsy (0.16, P < 0.05).
Correlations are given in Table 2. Because these correlations were weak, they cannot be
used to draw exact conclusions about the variations in immune reaction that occurred
during the trial.

Implications: The pigs in this natural infection experienced a variable response to
infection with PCV2. Evidence of infection was found in 77.4% of pigs at d49 in terms of
IgM response. Also the least square mean of viremia at this time point was 3.75 viral
DNA copies per mL serum (log 10) at this time point. However, only 16.1% of the pigs
had developed clinical symptoms of PCVAD. This is indicative that the patterns of
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immune response differed among the pigs. Some of the pigs that were infected showed
no clinical signs, and continued to grow at a normal rate throughout the experiment.
These pigs were ideal because they could overcome the effects of the virus and still
eventually reach a suitable market weight. Only a few of the pigs were very negatively
affected by the virus and suffered from respiratory complications and stunted growth. It is
important to be able to select against the pigs that showed clinical signs in order to have
pigs remain healthy and grow to their potential.
Although it was difficult to draw definitive conclusions because of a variance in
both timing of infection and amount of virus each pig was exposed to, it is important to
understand that the immune response mounted for each pig differed. This preliminary
study adequately set up the next trial to understand individual responses to infection with
PCV2 in two different lines.

2.3.2 TRIAL 2

Serology: All pigs used for the challenge came from dams that were vaccinated against
PCV2. The pigs received maternal antibodies, specifically IgG, through colostrum from
the dam at birth. Antibody decay varies in piglets but on average will wane by 5 to 21
weeks. Of the initial 120 candidates for infection, 75% had antibody levels low enough to
begin the infection process. This was determined by ELISA and a sample-to-positive
ratio of less than 0.3 for IgG. Overall, 82% of the Large White x Landrace (W x R) pigs
had IgG levels below the threshold (n = 82). Comparatively, 58% of the Duroc x Large
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White x Landrace [D (W x R)] had levels low enough to infect (n = 31). The levels of
IgG in the two crossbred groups did not differ (P > 0.1) before infection. Throughout the
trial, there was no difference in IgM (Figure 4) or IgG (Figure 5) levels between the two
genetic lines, W x R and [D (W x R)].
After infection, pigs were classified into one of three groups according to IgM
response. This is demonstrated in Figure 6. Those pigs that had the highest change in IgM
levels before d14 were classified as early responders (n = 33), and were placed in Group
1. Individuals that had the highest change in IgM levels after d14 fit into Group 2
(n = 40) and were called late responders. Group 3 consisted of pigs that did not respond
to infection (n = 7); that is, they did not have a noticeable change in IgM levels.
IgM levels during the experiment indicated that an infection had occurred and that
the barrows were building a primary response. At d7, there was no difference in IgM
levels between the three groups and the controls. At d14, Group 1 had the highest IgM
level with a mean of 1.38, whereas the mean for Groups 2 and 3 were 1.04 and 0.89,
respectively. At d21, Group 2 had the highest IgM levels at 2.02, whereas Group 3
remained the lowest and Group 1 was intermediate. At necropsy (d28), Group 2 remained
highest and Group 3 lowest. This indicates that in Group 3, with baseline IgM levels of
about 0.89 throughout the challenge, no quantifiable change in IgM levels occurred, and
therefore those pigs did not undergo a primary immune response (Figure 7).
There was no differences among the three groups in IgG levels, at d0 and 7. At
d14, Group 1 and Group 2 differed in IgG levels (P < 0.05). At d21, Group 1 differed
from Group 3 (P < 0.05), and there was a difference between Group 2 and 3 (P < 0.05) as
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well. At necropsy, Group 1 differed from Group 3 (P < 0.001) and Group 2 differed from
Group 3 (P < 0.0001) (Table 3).
Differences in both the magnitude and time of IgM response were observed
during the experimental challenge with PCV2b. The three groups of IgM response
experienced variance in response patterns (Figure 6). The chief difference between Group
1 and Group 2 was in the time of response. This was demonstrated by the peaks of IgM
before d14 in Group 1 and between d14 and d21 for Group 2. Because all of the pigs
were infected at the same time, and because there was no difference in IgG levels at d0
when infection occurred, it is unlikely that they had sufficient maternal antibodies to
attack the virus.
Group 3 differed from the other two groups in the magnitude of response. Levels
of IgG were higher in Group 1 than Group 3 at d21 and necropsy (P < 0.05 and
P < 0.001, respectively). Also, Group 2 had higher levels of IgG at d21 (P < 0.05) and
necropsy (P < 0.0001) (Table 3). Therefore, Group 3 was utilizing some other mechanism
to prevent infection from spreading throughout the body. There seemed to be an
inhibition of viral replication that allowed these pigs to remain healthy and avoid
subclinical signs of the virus.

PCV2 DNA in Serum: Quantitative PCR results for viral copy count indicated that all
barrows were PCV2 DNA negative at the day of infection. At all other time points, all of
the pigs that received the inoculation tested positive for infection with PCV2. Differences
in viral copy numbers between the two crossbred lines existed at d7 (P < 0.006) and d14
(P < 0.01) as illustrated in Figure 8. However, DNA copy number followed the same
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trend throughout the challenge for both lines: there was a steady increase in copy number
through d21, then a sharp decline thereafter.
Pigs in Group 3, those who had no noticeable change in IgM values, maintained
lower viral copy numbers than pigs in both Groups 1 and 2. At d7, Group 1 had the
highest response at 4.56 viral DNA copies per mL serum (log 10), whereas the response
in Group 3 was 3.85. At d14, Group 2 had the highest response with a mean of 5.24,
whereas the mean for Group 3 was only 4.27. At d21, the mean for Group 2 continued to
be highest, and Group 3 was lowest. At d28, the day necropsy was performed, Group 2
remained highest in viral copy count, while Group 3 remained lowest. Viremia area under
the curve (AUC), a measure of overall viral load throughout the challenge, revealed
Group 3 had the lowest AUC and thus the least viral load and Group 2 the highest.
Viremia in the control pigs remained baseline during the challenge and had no peaks or
spikes (Table 3).
The dose of inoculate administered to the pigs did not influence viral copy count,
with the exception of viremia results on d7 (P < 0.05). However, only four pigs showed
significant differences from the others, and they received the lowest dose of all groups of
infected pigs.

Clinical Evaluation: Only one death occurred during the 28-day experimental challenge.
This individual died during the fourth week of the challenge and displayed signs of a
wasting condition, as well as lethargy and a rough hair coat. According to quantitative
real-time PCR, this individual had the highest viral load three weeks after the challenge,
and was categorized in Group 1, the early response group.
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The only difference in growth occurred between Group 1 and 2 in terms of
average daily gain (ADG) during the entire 28-day period. Group 1 had an ADG for the
whole challenge of 0.42 kg, whereas pigs in Group 2 had an ADG of 0.36 kg for the
challenge (P < 0.05). Pigs in Group 3, those with no detectable immune response, had the
greatest ADG and a trend toward having the best growth rate (P = 0.19).

Genetic Characterization of the PCV2b Isolate: The strain isolated, sequenced, and
aligned from 12 infected individuals belongs to a PCV2b cluster and has the highest
similarity with strain FMV-05-6507. This strain has been shown to induce clinical signs
of PMWS and cause an increase in mortality rate. Upon alignment of the sequence used
for infection and the 12 sequences recovered from infected pigs, it was determined that
the strain used for infection was identical to the strain found in the 12 pigs whose DNA
was sequenced.

Genotyping: All 81 individuals from Trial 2 were genotyped using the PorcineSNP60
chip. The number of SNPs was 62,163 and the Low GenCall Score Cutoff was 0.15. The
average call rate was 99.65%, and the average number of calls for the 81 pigs was
59,687. The average heterozygosity of the 81 pigs was 33.8%. Figure 2 illustrates overlay
plots of minor allelic frequency versus SNP position at each chromosome for all pigs
genotyped in both trials. A similar approach was used to identify a chromosomal region
where clusters of SNPs are in Hardy Weinberg genetic equilibrium (Figure 3). These
figures are explained in the Section 2.3.1.
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Gene Associations: The software package ASREML was used to determine genomewide associations between the SNP genotypes and PCV2-specific traits- IgM, IgG,
viremia, and ADG. The association between SNP genotypes and IgM at d21 is illustrated
in Figure 9.
On chromosome 1, two SNPs were discovered. The first gene connected with a
SNP was syntaxin 11, also known as STX11. This gene encodes a member of the protein
group of syntaxins that works in intracellular movement. Syntaxin 11 is primarily
expressed in phagocytes and antigen presenting cells. Its role in vesicle trafficking may
play a role in the granule secretory pathway. This gene is known to cause familial
hemophagocytic lymphohistiocytosis in humans (Danielian et al., 2009).
Another SNP found on chromosome 1 was GNAQ, also known as guanine
nucleotide binding protein. This protein encodes the alpha subunit of heterotrimeric G
proteins. The role of these proteins is to attach the seven-transmembrane domain
receptors to allow for intracellular signaling (Van Raamsdonk et al., 2010). Mutations in
the protein cause a mutation known as dominant dark skin that is characterized by
increased dermal melanin (Emley et al., 2011).
A SNP on chromosome 6 associated with IgM was close to the interleukin 34 (IL34) gene. Interleukin 34 is found in many tissues of the human, including lung, liver,
kidney, and in abundance in the spleen. This member of the cytokine family plays a role
in regulation of myeloid cell growth and differentiation. It has also been shown to
encourage the formation of a macrophage progenitor in human bone marrow cultures
(Lin et. al, 2008).
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In addition, there were two possible SNPS associated with IgM on chromosome
14. The first, positioned near the G protein-coupled receptor kinase 5 gene (GRK5), is in
family of serine/threonine kinases that assist phosphorylation of seven-transmembranespanning G protein-coupled receptors. The variety of receptors that they have effects on
include adrenergic, muscarinic, and chemokine receptors. The fifth kinase in the family
specifically phosphorylates a transcriptional factor and tumor suppressant, p53, which is
a regulator of both apoptosis and proliferation. In mice, deletion of GRK5 results in
hypothermia, hypoactivity, tremors, and increased salivation (Chen et al., 2010).
Last, also on chromosome 14 was a SNP located near the TIAL1 locus (TIA1
cytotoxic granule-associated RNA binding protein-like 1). This protein is involved in
nuclear and cytoplasmic RNA metabolism, and is important in splicing regulation in
mammals. It also has been found to be a translational regulator to assist cellular and
virus-induced apoptosis, specifically by adapting the cellular response to deal with
metabolic stress and inflammation (Bossowski et al., 2010).

Correlations: Moderate negative correlations existed between average daily gain (ADG)
and viremia area under the curve (AUC) for several time points. These values are located
in Table 4. Viremia AUC from d0 to d7 was correlated with ADG for the whole
challenge (-0.22, P < 0.05). Viremia AUC from d0 to d14 had a correlation of -0.24 with
ADG for the whole challenge (P < 0.05). The correlation between AUC from d0 to d21
and ADG from d0 to d28 was -0.27 (P < 0.05). The strongest correlation was between
AUC for the whole trial and ADG for the whole trial at -0.29 (P < 0.01). This correlation
indicated that the higher the viral load of the pig, the less it would be able to put on
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weight and grow to its genetic potential. Figure 10 illustrates the correlation between the
Z score values for AUC PCV2 copy number and ADG, with each dot representing a pig.
Pigs in the lower right corner demonstrated the most desirable phenotype, with the
highest grow rates and the lowest viremia.
These correlations help to understand the effects of disease progression of PCV2
on pigs in the grow-finish stage. Pigs with high viremic conditions struggle to catch up
with their littermates and siblings because with viral replication comes certain wasting
conditions. Though it has not been demonstrated that feed intake suffers during a period
of experimental infection such as this, it has been shown in numerous studies that growth
has been stunted in pigs infected with PCV2.
A study done by Blanchard et al. (2003) compared vaccinated pigs to
unvaccinated pigs in terms of PMWS disease progression. They challenged 28 pigs of
various immune statuses, with one group being unvaccinated. Ten to 14 days after
infection, all of the challenge-control group (pigs that were not vaccinated and were
challenged with the virus) developed both pyrexia and growth retardation. On the other
hand, pigs inoculated against the virus had significantly higher growth at both the second
and third week post infection.
Albina et al. (2001) found similar results when they studied the effects of direct
transmission on piglets. Two of the piglets with signs of PMWS before the experiment
showed signs of emaciation, weakness, and had a high rate of weight loss. These two
piglets had to be euthanized before the trial ended. The rest of the piglets underwent one
of their nine trials and were either inoculated with PCV2 or kept as controls. It was
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shown that all infected pigs developed both pyrexia and growth retardation after about 13
days of infectious status.

Implications: Differences in the magnitude and time of IgM response was observed
during experimental challenge with PCV2b. The difference between Group 1 and Group
2 was in the time of response, while the difference between Groups 1 and 2 and Group 3
was in the magnitude of response. Group 3 had the lowest viral copy count and the
highest growth, most likely due to a mechanism that inhibited viral replication. The pigs
in Group 3 demonstrated the most desirable phenotype, one in which the pigs’ immune
system never mounted a response to the disease while also having the propensity toward
having the best growth rates. Following studies will be aimed at understanding and
characterizing the mechanism in which these pigs deal with a viral infection such as
PCV2. Once research has been completed to explain the response to viruses, selection
against those pigs susceptible for PCVAD will lead to healthier, faster growing pigs.
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2.4 CONCLUSION

The results of this preliminary research provide evidence of a significant variation
in immune response from one individual to another. The natural infection illustrated that
some infected pigs showed clinical signs to the disease while other infected pigs did not
elicit symptoms. It also helped explain transmission patterns and virus progression. The
experimental challenge revealed three groups of pigs that differed greatly in both
antibody response and viral copy count numbers. It also demonstrated that some pigs
utilized a mechanism of inhibition of viral replication that is not clearly understood.
With a virus like PCV2, several challenges exist. First, the virus is present
everywhere in the world, and is very hard to disinfect against. Almost every herd in the
United States has been exposed to the virus. This makes the development of pigs that are
specific pathogen free for PCV2 extremely difficult. Sows must to be vaccinated against
the virus to protect against stillborns, abortions, and fetal mummies. This creates
logistical problems because piglets must be virtually free of maternal antibodies to
accurately simulate a disease challenge. Therefore, a waiting period must be undergone
that differs for every pig. Knowing and synchronizing when each pig is ready for
infection is a practical factor to consider. In the case of a natural infection, it becomes
difficult to understand infection dynamics when there is such a variation in infection.
When the exact timing of the occurrence of infection cannot be determined, the variation
in response times and magnitudes is due to numerous uncontrollable factors. In addition
to the standard environmental and litter effects, pigs infected at different times with
different amounts of virus cannot be uniformly studied.
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Another challenge is that pigs must be closely monitored to catch clinical
symptoms and subclinical infections. This means frequent bleedings to test for anti-PCV2
antibodies and viremic conditions. Regular bleedings, more frequent than once a week,
can put a strain on the pigs, as well as require an immense amount of labor and time.
Sensitive tests such as ELISA work well for diagnosis, but make the question of exact
timing of infection difficult unless the pig is bled daily, a practice that can put the animal
in danger.
In Trial 2, the experimental infection, there were clear differences in the groups of
pigs that had an early or late response versus the group showing no response. A lack of
immune response has several explanations. One such elucidation is that the pigs were
infected with different strains of the virus. Since pigs are so susceptible to pathogens in
new environments, this argument is relevant. However, upon isolation and sequencing of
the virus from four pigs in each IgM group (1, 2, and 3), the virus infecting the animals
was found to be identical. This indicates that the lack of response to infection of the
Group 3 pigs cannot be attributed to a difference in virulence.
Another possible suggestion is that the pigs had variable levels of maternal
antibodies (IgG) circulating in their system from colostrum at the time of birth. However,
the IgG ELISA confirmed that pigs in each group had no significant differences in IgG
levels at d0 before infection (P > 0.05). All three groups of pigs, as well as the controls,
were negative for maternal antibodies, thus the reason they were selected for the
experiment. A difference in maternal antibodies cannot explain the variation in IgM
response of the three groups.
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A genetic effect could certainly exist. Because the groups of pigs constituted two
genetic lines, the incidence of viral infection could be due to a susceptibility factor.
However, analysis of the two lines indicated that there was no significant difference in
viremia, IgG, IgM, or weight gain between the Large White x Landrace pigs and the
Duroc x (Large White x Landrace) pigs. Although a genetic component to disease
resistance has been demonstrated in several studies, the variation in response in this study
cannot be solely attributed to genetics.
There is significant evidence that selection for disease resistance is not only
possible but also may answer many questions. However, without a panel of reliable
markers, selection criteria are lacking. Genome-wide association studies to better
understand the genes responsible for resistance to diseases may be key to understating a
complex disease like PCV2. More research is needed to establish an extensive database
of not only phenotypes but also genotypes, SNPs, and candidate genes to better
understand progression and prevention of the virus. In order to achieve this, many more
experimental infections must be conducted to better understand the mechanisms, timing,
and variance in response to PCV2 infection.
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TABLES

Table 1. Primers and probe sequences used for qRT-PCV and cDNA sequencing of
PCV2b - Trial 1 and 2.
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Table 2. Correlations between IgM, IgG, and change in weight at all timepoints - Trial 1.

Change in Wt, d1 to d14

Change in Wt, d14 to d49

Wt Change Total

IgM d14

-0.02

0.10

0.07

IgG d14

-0.08

0.13

0.07

IgM d49

0.12

-0.01

0.03

IgG d49

0.24

a

0.05

0.12

IgM Necropsy

-0.03

-0.08

-0.07

IgG Necropsy

0.16a

0.06

0.10

a

Indicates P < 0.05
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Table 3. Least Squares Means of the parameters profiled during challenge in the groups
of individuals that showed different patterns in immune response to infection - Trial 21.

Group
Trait
ADG, 0 to 7 d.p.i.2
ADG, 7 to 14
ADG, 14 to 21
ADG, 21 to 28
ADG, 0 to 28
IgG 0
IgG 7
IgG 14
IgG 21
IgG 28
Viremia 7
Viremia 14
Viremia 21
Viremia 28
Viremia AUC

1
n = 33
0.21
0.36
0.49
0.59
0.42a
0.76
0.75e
0.68a
1.71c,a
1.89g,e
4.56e
5.16g,a
5.8g,c
4.66g
124.11g,d

2
n = 40
0.15
0.32
0.43
0.53
0.36b
0.79
0.78c
0.61b
1.83e,a
2.08g,i
4.37c
5.24g,a
6.17g,e
4.7g,a
127.53g,d

3
n=7
0.18
0.37
0.47
0.63
0.43
0.68
0.75c
0.61
0.91b
0.74f,j
3.85
4.27g,b
4.67f,d
3.96c,b
104.06c

Control
n=9
0.21
0.37
0.55
0.53
0.42
0.83
0.94f,d
0.69
0.70f,d
0.56h
3.22f,d
2.13h
3.79h
2.56h,d
72.991h,d

1

The infected individuals were separated in groups based on their response to infection as 1) early 2) late
and 3) no response to infection.
Significant differences between groups are represented with different superscripts in the same row as
follows: a,b P < 0.05, c,d P < 0.01, e,f P < 0.001 and g,h P < 0.0001 or i,jP < 0.0001.
2

Units for ADG are kilograms of gain per day; units for IgG are sample-to-positive ratio; units for viremia
are viral DNA copies per ml serum (log 10).
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Table 4. Correlations between weight gain and viral load - Trial 2.

ADG
0 to 7
ADG
0 to 14
ADG
0 to 21
ADG
0 to 28
AUC
0 to 7
AUC
0 to 14
AUC
0 to 21
AUC
0 to 28
a

ADG
0 to 7
1.00

ADG
0 to 14
0.83

ADG
0 to 21
0.74

ADG
0 to 28
0.66

AUC
0 to 7
-0.01

AUC
0 to 14
-0.02

AUC
0 to 21
-0.03

AUC
0 to 28
-0.04

0.83

1.00

0.88

0.82

-0.12

-0.12

-0.11

-0.12

0.74

0.88

1.00

0.92

-0.17

-0.17

-0.18

-0.20

0.66

0.82

0.92

1.00

-0.22

-0.24

-0.27

-0.29

-0.01

-0.12

-0.17

-0.22

1.00

0.96

0.84

0.78

-0.02

-0.12

-0.17

-0.24

0.96

1.00

0.95

0.90

-0.03

-0.11

-0.18

-0.27

0.84

0.95

1.00

0.99

-0.04

-0.12

-0.20

-0.29

0.78

0.90

0.99

1.00

Indicates P < 0.05 and b indicates P < 0.01

a

a

a

b
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FIGURES

Figure 1. Log 10 of viral copy number for two crossbred lines - Trial 1.
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Figure 2. Overlay plots of Minor Allelic Frequency vs. SNP Position
for each chromosome - Trial 1 and 2.
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Figure 3. Overlay plots of Hardy Weinberg Chi-Square Values vs. SNP Position
for each chromosome - Trial 1 and 2.
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Figure 4. IgM sample to positive ratios (S/P) during the experimental challenge of two
crossbred lines - Trial 2. Large White x Landrace pigs are denoted W x R, while Duroc
(Large White x Landrace) pigs are denoted D (W x R).
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Figure 5. IgG sample to positive ratios (S/P) during the experimental challenge of
two crossbred lines - Trial 2. Large White x Landrace pigs are denoted W x R, while
Duroc (Large White x Landrace) pigs are denoted D (W x R).
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Figure 6. Individual patterns of IgM response to an experimental PCV2 infection Trial 21.

1

Infected individuals display different patterns of response to infection as: 1) early response- solid black;
2) late response- solid grey; 3) no response- dashed black.
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Figure 7. Least Square Means of IgM sample to positive ratios (S/P) profile during
PCV2b experimental infection based on grouping by IgM response - Trial 2.
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Figure 8. Log 10 of viral copy number for the two crossbred lines - Trial 2. Large White
x Landrace pigs are denoted W x R, while Duroc (Large White x Landrace) pigs are
denoted D (W x R).
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Figure 9. Genome wide associations between SNP genotypes and PCV2-specific IgM at
d21 - Trial 21.

1

The X-axis represents the location of the SNPs from SSC1 to 18, SSCX and a group of SNPs (represented
in grey) without a precise location. Y-axis represents the F value. Each dot represents the F value
corresponding to the additive effect of a SNP.
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Figure 10. Individual correlations between ADG and viremia AUC based on grouping by
IgM response - Trial 2. Axes represent Z score values for ADG on the x axis and AUC
PCV2 copy number on the y axis.

Overall correlation: r = -0.29 (p < 0.01)
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APPENDIX
Appendix Ia. Genome wide associations between SNP genotypes and traits measured in
Trial 1- additive effects.
ADG d0 to d14 (t > 21.6 corresponds to a FDR < 0.11)

ADG d14 to d49 (t > 19.0 corresponds to a FDR < .1)

ADG d0 to d49 (t > 9.3 corresponds to a FDR < 0.3)
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IgG d14 (t > 8.6 corresponds to a FDR < 0.4)

IgG d49 (t > 17 corresponds to a FDR < 0.78 )

IgG Necropsy (t > 9.5 corresponds to a FDR < 0.4 )
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IgM d14 (t > 11.2 corresponds to a FDR < 0.2)

IgM d49 (t > 13.1 corresponds to a FDR < 0.4)

IgM Necropsy (t > 8.9 corresponds to a FDR < 0.7)
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Viremia d49 (t > 8.7 corresponds to a FDR < 0.6)

Viremia Necropsy (t > 9.2 corresponds to a FDR < 0.9)

Viremia AUC (t > 5.9 corresponds to a FDR < 0.81)
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Appendix Ib. Genome wide associations between SNP genotypes and traits measured in
Trial 1- dominance effects.

ADG d0 to d14 (t > 5.37 corresponds to a FDR < 0.9)

ADG d14 to d49 (t > 13.7 corresponds to a FDR < 0.2)

ADG d0 to d49 (t > 13.6 corresponds to a FDR < 0.3)

IgG d14 (t > 6.0 corresponds to a FDR < 0.7)

IgG d49 (t > 13.2 corresponds to a FDR < 0.71)

IgG Necropsy (t > 9.0 corresponds to a FDR < 0.6)
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IgM d14 (t > 17.4 corresponds to a FDR < 0.1)

IgM d49 (t > 6.3 corresponds to a FDR < 0.8)

IgM Necropsy (t > 7.6 corresponds to a FDR < 0.5)
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Viremia d49 (t > 9.9 corresponds to a FDR < 0.3)

Viremia Necropsy (t > 13.9 corresponds to a FDR < 0.6)

Viremia AUC (t > 6.0 corresponds to a FDR < 0.9)
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Appendix IIa. Genome wide associations between SNP genotypes and traits measured in
Trial 2- additive effects.

ADG d0 to d7 (t > 10.0 corresponds to a FDR < 0.2)

ADG d7 to d14 (t > 20.3 corresponds to a FDR < 0.45)

ADG d14 to d21 (t > 26 corresponds to a FDR < 0.085)
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ADG d21 to Necropsy (t > 11.5 corresponds to a FDR < 0.1)

IgG d0 (t > 10.8 corresponds to a FDR < 0.3)

IgG d7 (t > 5.9 corresponds to a FDR < 0.4)
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IgG d14 (t > 6.8 corresponds to a FDR < 0.6)

IgG d21 (t > 7.2 corresponds to a FDR < 0.6)

IgG Necropsy (t > 7.1 corresponds to a FDR < 0.5)

108
IgM d0 (t > 9.3 corresponds to a FDR < 0.9)

IgM d7 (t > 11.0 corresponds to a FDR < 0.4)

IgM d14 (t > 15.2 corresponds to a FDR < 0.1)
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IgM d21 (t > 6.2 corresponds to a FDR < 0.5)

IgM Necropsy (t > 9.8 corresponds to a FDR < 0.2)

Viremia d7 (t > 11.2 corresponds to a FDR < 0.7)
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Viremia d14 (t > 5.8 corresponds to a FDR < 0.4)

Viremia d21 (t > 8.8 corresponds to a FDR < 0.3)

Viremia Necropsy (t > 8.5 corresponds to a FDR < 0.5)

Viremia AUC (t > 25.6 corresponds to a FDR < 0.1)
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Appendix IIb. Genome wide associations between SNP genotypes and traits measured in
Trial 2- dominance effects.
ADG d0 to d7 (t > 5.5 corresponds to a FDR < 0.7)

ADG d7 to d14 (t > 12.0 corresponds to a FDR < 0.999)

ADG d14 to d21 (t > 9.4 corresponds to a FDR < 0.6)
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ADG d21 to Necropsy (t > 5.0 corresponds to a FDR < 0.5)

IgG d0 (t > 11.2 corresponds to a FDR < 0.3)

IgG d7 (t > 7.6 corresponds to a FDR < 0.3)
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IgG d14 (t > 5.6 corresponds to a FDR < 0.7)

IgG d21 (t > 7.2 corresponds to a FDR < 0.7)

IgG Necropsy (t > 7.0 corresponds to a FDR < 0.5)
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IgM d0 (t > 11.4 corresponds to a FDR < 0.7)

IgM d7 (t > 11.8 corresponds to a FDR < 0.3)

IgM d14 (t > 13.3 corresponds to a FDR < 0.3)
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IgM d21 (t > 5.9 corresponds to a FDR < 0.8)

IgM Necropsy (t > 7.0 corresponds to a FDR < 0.4)

Viremia d7 (t > 11.5 corresponds to a FDR < 0.9)
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Viremia d14 (t > 6.8 corresponds to a FDR < 0.6)

Viremia d21 (t > 10.2 corresponds to a FDR < 0.2)

Viremia Necropsy (t > 8.1 corresponds to a FDR < 0.9)
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Viremia AUC (t > 10.5 corresponds to a FDR < 0.4)

